Aytu BioPharma (AYTU) 10-Q 17 May 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2021	May 10, 2021
Document Information [Line Items]
Entity Registrant Name	AYTU BIOPHARMA, INC
Entity Central Index Key	0001385818
Trading Symbol	aytu
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		25,170,596
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2021	Jun. 30, 2020
Current assets
Cash and cash equivalents	$ 46,537,958	$ 48,081,715
Restricted cash	251,995	251,592
Accounts receivable, net	28,228,434	5,632,717
Inventory	16,575,757	9,999,441
Prepaid expenses	6,803,583	5,715,089
Other current assets	1,615,024	5,742,011
Total current assets	100,012,751	75,422,565
Fixed assets, net	5,557,727	258,516
Operating lease right-of-use asset	3,781,737	634,093
Intangible assets, net	96,236,796	48,854,561
Goodwill	65,802,636	28,090,407
Other long-term assets	164,954	32,981
Total long-term assets	171,543,850	77,870,558
Total assets	271,556,601	153,293,123
Current liabilities
Accounts payable and other	16,528,646	11,824,560
Accrued liabilities	43,181,920	8,645,984
Accrued compensation	10,510,228	3,117,177
Notes payable		982,076
Short-term line of credit	4,738,825
Current portion of debt	725,357
Current portion of operating lease liabilities	910,885	300,426
Current portion of fixed payment arrangements	1,998,012	2,340,166
Current portion of CVR liabilities	911,826	839,734
Current portion of contingent consideration	4,177,282	713,251
Total current liabilities	83,682,981	28,763,374
Long-term debt, net of current portion	16,930,682
Long-term operating lease liability, net of current portion	2,871,845	725,374
Long-term fixed payment arrangements, net of current portion	9,422,768	11,171,491
Long-term CVR liabilities, net of current portion	4,679,227	4,731,866
Long-term contingent consideration, net of current portion	10,726,691	12,874,351
Other long-term liabilities	92,894	11,371
Total liabilities	128,407,088	58,277,827
Commitments and contingencies (Note 10)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; shares issued and outstanding 0 and 0, respectively as of March 31, 2021 and June 30, 2020, respectively.
Common Stock, par value $.0001; 200,000,000 shares authorized; shares issued and outstanding 23,457,887 and 12,583,736, respectively as of March 31, 2021 and June 30, 2020.	2,346	1,259
Additional paid-in capital	302,448,362	215,024,216
Accumulated deficit	(159,301,195)	(120,010,179)
Total stockholders' equity	143,149,513	95,015,296
Total liabilities and stockholders' equity	$ 271,556,601	$ 153,293,123

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2021	Jun. 30, 2020
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	23,457,887	12,583,736
Common stock, shares outstanding (in shares)	23,457,887	12,583,736

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Revenues
Product revenue, net	$ 13,482,282	$ 8,156,173	$ 42,149,561	$ 12,771,235
Operating expenses
Cost of sales	13,682,297	1,998,659	23,499,842	2,980,425
Research and development	389,262	78,502	858,698	223,197
Selling, general and administrative	12,851,087	9,190,386	35,825,175	19,494,368
Acquisition related costs	1,536,800	311,083	2,849,037	1,533,723
Restructuring costs	4,818,064		4,874,723	135,981
Amortization and impairment of intangible assets	5,870,436	1,370,986	9,039,597	2,899,553
Total operating expenses	39,147,946	12,949,616	76,947,072	27,267,247
Loss from operations	(25,665,664)	(4,793,443)	(34,797,511)	(14,496,012)
Other (expense) income
Other (expense), net	(425,425)	(538,862)	(1,555,924)	(1,181,206)
Gain / (Loss) from change in fair value of contingent consideration	631,298		(2,680,022)
Gain from derecognition of contingent consideration				5,199,806
Gain from warrant derivative liability				1,830
Loss on debt exchange			(257,559)
Total other (expense) income	205,873	(538,862)	(4,493,505)	4,020,430
Net loss	$ (25,459,791)	$ (5,332,305)	$ (39,291,016)	$ (10,475,582)
Weighted average number of common shares outstanding (in shares)	18,092,465	3,527,530	14,490,219	2,261,697
Basic and diluted net loss per common share (in dollars per share)	$ (1.41)	$ (1.51)	$ (2.71)	$ (4.63)

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Series F Preferred Stock [Member]Preferred Stock [Member]	Series F Preferred Stock [Member]Common Stock [Member]	Series F Preferred Stock [Member]Additional Paid-in Capital [Member]	Series F Preferred Stock [Member]Retained Earnings [Member]	Series F Preferred Stock [Member]	Warrants Issued in Connection with Registered Offering [Member]Preferred Stock [Member]	Warrants Issued in Connection with Registered Offering [Member]Common Stock [Member]	Warrants Issued in Connection with Registered Offering [Member]Additional Paid-in Capital [Member]	Warrants Issued in Connection with Registered Offering [Member]Retained Earnings [Member]	Warrants Issued in Connection with Registered Offering [Member]	Warrants Issued to Placement Agents in Connection with Registered Offering [Member]Preferred Stock [Member]	Warrants Issued to Placement Agents in Connection with Registered Offering [Member]Common Stock [Member]	Warrants Issued to Placement Agents in Connection with Registered Offering [Member]Additional Paid-in Capital [Member]	Warrants Issued to Placement Agents in Connection with Registered Offering [Member]Retained Earnings [Member]	Warrants Issued to Placement Agents in Connection with Registered Offering [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
BALANCE (in shares) at Jun. 30, 2019																3,594,981	1,753,808
BALANCE at Jun. 30, 2019																$ 359	$ 176	$ 113,476,783	$ (106,389,500)	$ 7,087,818
Stock-based compensation																		165,171		165,171
Preferred stock converted in common stock (in shares)																(443,833)	44,384
Securities converted for common stock																$ (44)	$ 5	39
Net loss																			(4,929,030)	(4,929,030)
BALANCE (in shares) at Sep. 30, 2019																3,151,148	1,798,192
BALANCE at Sep. 30, 2019																$ 315	$ 181	113,641,993	(111,318,530)	2,323,959
BALANCE (in shares) at Jun. 30, 2019																3,594,981	1,753,808
BALANCE at Jun. 30, 2019																$ 359	$ 176	113,476,783	(106,389,500)	7,087,818
Net loss																				(10,475,582)
BALANCE (in shares) at Mar. 31, 2020																9,805,845	10,061,044
BALANCE at Mar. 31, 2020																$ 981	$ 1,011	202,566,906	(116,865,082)	85,703,816
BALANCE (in shares) at Sep. 30, 2019																3,151,148	1,798,192
BALANCE at Sep. 30, 2019																$ 315	$ 181	113,641,993	(111,318,530)	2,323,959
Stock-based compensation																		162,264		162,264
Preferred stock converted in common stock (in shares)																(2,751,148)	275,115
Securities converted for common stock																$ (275)	$ 28	247
Net loss																			(214,247)	(214,247)
Issuance of stock (in shares)	10,000
Issuance of stock	$ 1		$ 5,249,483		$ 5,249,484
Warrants issued																		4,008,866		4,008,866
Issuance of preferred stock due to acquisition (in shares)																9,805,845
Issuance of preferred stock due to acquisition																$ 981		5,558,933		5,559,914
BALANCE (in shares) at Dec. 31, 2019																10,215,845	2,073,307
BALANCE at Dec. 31, 2019																$ 1,022	$ 209	128,621,786	(111,532,777)	17,090,240
Issuance costs					$ (741,650)
Preferred stock converted in common stock (in shares)																(2,407,902)	1,239,791
Securities converted for common stock																$ (241)	$ 124	92,997		92,880
Net loss																			(5,332,305)	(5,332,305)
Issuance of stock (in shares)																	3,636,528
Issuance of stock																	$ 364	33,278,392		33,278,756
Warrants issued								$ 9,723,161		$ 9,723,161			$ 1,458,973		$ 1,458,973
Issuance of preferred stock due to acquisition (in shares)																1,997,902	380,972
Issuance of preferred stock due to acquisition																$ 200	$ 39	4,405,945		4,406,184
Stock-based compensation (in shares)																	106,792
Stock-based compensation																	$ 11	263,380		263,391
Cashless warrant exercise (in shares)																	791,577
Cashless warrant exercise																	$ 80	(80)
Warrant exercises (in shares)																	1,708,300
Warrant exercises																	$ 171	22,989,495		22,989,666
CVR payouts (in shares)																	123,777
CVR payouts																	$ 13	1,732,857		1,732,870
BALANCE (in shares) at Mar. 31, 2020																9,805,845	10,061,044
BALANCE at Mar. 31, 2020																$ 981	$ 1,011	202,566,906	(116,865,082)	85,703,816
Issuance costs																				(4,523,884)
BALANCE (in shares) at Jun. 30, 2020																	12,583,736
BALANCE at Jun. 30, 2020																	$ 1,259	215,024,216	(120,010,179)	95,015,296
Stock-based compensation																		454,918		454,918
Net loss																			(4,305,931)	(4,305,931)
BALANCE (in shares) at Sep. 30, 2020																	12,583,736
BALANCE at Sep. 30, 2020																	$ 1,259	215,377,597	(124,316,110)	91,062,746
Issuance costs																		(101,537)		(101,537)
BALANCE (in shares) at Jun. 30, 2020																	12,583,736
BALANCE at Jun. 30, 2020																	$ 1,259	215,024,216	(120,010,179)	95,015,296
Net loss																				(39,291,016)
BALANCE (in shares) at Mar. 31, 2021																	23,457,887
BALANCE at Mar. 31, 2021																	$ 2,346	302,448,362	(159,301,195)	143,149,513
BALANCE (in shares) at Sep. 30, 2020																	12,583,736
BALANCE at Sep. 30, 2020																	$ 1,259	215,377,597	(124,316,110)	91,062,746
Stock-based compensation																		508,059		508,059
Preferred stock converted in common stock (in shares)																	130,081
Securities converted for common stock																	$ 13	1,057,546		1,057,559
Net loss																			(9,525,294)	(9,525,294)
Issuance of stock (in shares)																	5,169,076
Issuance of stock																	$ 516	28,316,928		28,317,444
Warrants issued																		1,272,154		1,272,154
BALANCE (in shares) at Dec. 31, 2020																	17,882,893
BALANCE at Dec. 31, 2020																	$ 1,788	246,532,284	(133,841,404)	112,692,668
Stock-based compensation																		1,381,429		1,381,429
Net loss																			(25,459,791)	(25,459,791)
Issuance of preferred stock due to acquisition (in shares)																	5,471,804
Issuance of preferred stock due to acquisition																	$ 548	53,102,370		53,102,918
CVR payouts (in shares)																	103,190
CVR payouts																	$ 10	999,990		1,000,000
BALANCE (in shares) at Mar. 31, 2021																	23,457,887
BALANCE at Mar. 31, 2021																	$ 2,346	302,448,362	(159,301,195)	143,149,513
Issuance costs																				(137,735)
Estimated fair value of replacement equity awards																		$ 432,289		$ 432,289

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($)	3 Months Ended
	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Series F Preferred Stock [Member]
Issuance costs				$ 741,650
Issuance costs	$ 137,735	$ 101,537	$ 4,523,884

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Activities
Net loss	$ (39,291,016)	$ (10,475,582)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation, amortization and accretion	10,301,150	3,780,310
Stock-based compensation expense	2,485,330	590,826
Loss from change in fair value of contingent consideration	2,680,022
Inventory write-down	7,227,230	0
(Gain) from derecognition of contingent consideration		(5,199,806)
(Gain) on the change in fair value of CVR payout		(267,130)
Amortization of senior debt issuance costs and discounts	(21,916)
Loss on sale of equipment	112,110
(Gain) on termination of lease	(343,185)
Loss on debt exchange	257,559
Changes in allowance for bad debt	335,036
Derivative income		(1,830)
Changes in operating assets and liabilities:
Accounts receivable	1,772,274	(8,183,810)
Inventory	(4,390,470)	(345,452)
Prepaid expenses	1,607,170	(1,611,681)
Other current assets	6,065,996	(358,022)
Accounts payable and other	(6,155,583)	(4,912,245)
Accrued liabilities	(5,556,614)	6,761,319
Accrued compensation	3,263,723	271,560
Fixed payment arrangements		(657,655)
Operating lease liabilities	(26,648)
Net cash used in operating activities	(19,677,832)	(20,609,198)
Investing Activities
Deposit	(3,923)
Contingent consideration payment	(683,241)	(151,648)
Cash received from acquisition	15,721,797	390,916
Cash payment for business acquisition	(15,398,727)	(5,850,000)
Net cash used in investing activities	(364,094)	(5,610,732)
Financing Activities
Issuance of preferred, common stock and warrants	32,249,652	58,999,666
Issuance cost related to registered offering	(4,430,516)	(5,280,426)
Payments made on short-term line of credit	(5,968,290)
Warrant exercises		22,989,666
Preferred stock converted in common stock		92,880
Issuance of note payable		640,000
Debt payment	(318,181)
Payments made to fixed payment arrangements	(3,034,093)
Net cash provided by financing activities	18,498,572	77,441,786
Net change in cash, restricted cash and cash equivalents	(1,543,354)	51,221,856
Cash, restricted cash and cash equivalents at beginning of period	48,333,307	11,294,227
Cash, restricted cash and cash equivalents at end of period	46,789,953	62,516,083
Supplemental disclosures of cash and non-cash investing and financing transactions
Warrants issued to underwriters	1,628,293
Cash paid for interest	448,603	392,641
Fair value of right-to-use asset and related lease liability	66,182	354,929
Fair value of non-cash assets acquired	104,321,912
Fair value of liabilities assumed	88,699,892
Estimated fair value of replacement equity awards	432,289
Inventory payment included in accounts payable		460,416
Return deductions received by Cerecor		2,000,000
Contingent value rights payout	1,000,000
Contingent consideration included in accounts payable		27,571
Issuance of restricted stock		107
Cashless warrant exercises		792
Debt exchange	1,057,559
Fixed payment arrangements included in accrued liabilities	1,575,000	501,766
Exchange of convertible preferred stock into common stock		92,880
Conversion of Convertible Preferred Stock into Common Stock [Member]
Financing Activities
Preferred stock converted in common stock		1,559
Supplemental disclosures of cash and non-cash investing and financing transactions
Exchange of convertible preferred stock into common stock		1,559
Neos Therapeutics, Inc. [Member]
Supplemental disclosures of cash and non-cash investing and financing transactions
Issuance of stock	53,240,653
Series G Preferred Stock [Member] | Cerecor Portfolio of Pediatrics Therapeutics [Member]
Supplemental disclosures of cash and non-cash investing and financing transactions
Issuance of stock		5,559,914
Series H Preferred Stock [Member] | Innovus [Member]
Supplemental disclosures of cash and non-cash investing and financing transactions
Issuance of stock		$ 12,805,263

Note 1 - Nature of Business, Fi

Note 1 - Nature of Business, Financial Condition, Basis of Presentation	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Nature of Business. August 9, 2002 June 8, 2015. The Rx Portfolio consists of (i) Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets and Adzenys-ER (amphetamine) extended-release oral suspension for the treatment of attention deficit hyperactivity disorder (ii) Poly-Vi-Flor and Tri-Vi-Flor, two 12 The Consumer Health Portfolio consists of over twenty On March 31, 2021, July 29, 2019 $7.5 $250,000 30 On March 19, 2021, three In April 2020, 2 2 The Company's strategy is to continue building its portfolio of revenue-generating products, leveraging its commercial team's expertise to build leading brands within large therapeutic markets. Financial Condition. March 31, 2021 $46.8 Revenues for the three nine March 31, 2021 $13.5 $42.1 $8.2 $12.8 March 31, 2020, 65% 230%, nine March 31, 2021 $19.7 $20.6 nine March 31, 2020 As of the date of this Report, the Company expects its costs for operations to increase as the Company integrates the Neos acquisition, invests in new product development, continues to focus on revenue growth through increasing product sales and additional acquisitions. The Company's current assets totaling approximately $100.0 March 31, 2021 may may no March 19, 2021, $15.4 $5.5 not three March 31, 2021. As of the date of this report, the Company has adequate capital resources to complete its near-term operating objectives. Since the Company has sufficient cash on-hand as of March 31, 2021 twelve no If the Company is unable to raise adequate capital in the future when it is required, the Company's management can adjust its operating plans to reduce the magnitude of the Company's capital need under its existing operating plan. Some of the adjustments that could be made include delays of and reductions to commercial programs, reductions in headcount, narrowing the scope of the Company's commercial plans, or reductions or delays to its research and development programs. Without sufficient operating capital, the Company could be required to relinquish rights to products or renegotiate to maintain such rights on less favorable terms than it would otherwise choose. This may Basis of Presentation. 10 June 30, 2020 March 31, 2021 not March 31, 2021 three nine March 31, 2021 2020 On December 8, 2020, one 10 Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent consideration, contingent value rights ("CVRs"), and fixed payment obligations at the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not Reclassification The Company historically presented accrued distributor fees as a reduction to accounts receivable. However, beginning this quarterly report and for the comparative periods presented, accrued distributors fees will be presented in accrued liabilities instead of accounts receivable. As of June 30, 2020, $457,000 . no Significant Accounting Policies The Company's significant accounting policies are discussed in Note 2—Summary no three nine March 31, 2021 Adoption of New Accounting Pronouncements Fair Value Measurements ( ASU 2018 13 ). August 2018, 2018 13, 820 2018 13 820, December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 July 1, 2020, June 30, 2021. 2018 13 3 3 Recent Accounting Pronouncements Financial Instruments Credit Losses ( ASU 2016 13 ). June 2016, 2016 13, December 15, 2019. October 2019, December 15, 2022. June 30, 2024. December 15, 2018, not 2016 13 no This Quarterly Report on Form 10 not not

Note 2 - Acquisitions

Note 2 - Acquisitions	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	2. The Pediatric Portfolio On October 10, 2019, November 1, 2019. four $4.5 980,000 not $2.7 $0.8 $3.5 In addition, the Company assumed Cerecor obligations due to an investor that include fixed and variable payments aggregating to $25.6 $0.1 November 2019 January 2021 $15.0 January 2021. 15% $0.1 January 2020, one $0.2 $9.5 February 12, 2026. June 2020, $15.0 January 2021 Further, certain of the products in the Pediatric Portfolio require royalty payments ranging from 12% 15% $2.1 not While no 805. The following table summarized the fair value of assets acquired and liabilities assumed at the date of acquisition. As of November 1, 2019 Consideration Cash and cash equivalents $ 4,500,000 Fair value of Series G Convertible Preferred Stock Total shares issued 9,805,845 Estimated fair value per share of Aytu common stock $ 0.567 Estimated fair value of equity consideration transferred 5,559,914 Total consideration transferred $ 10,059,914 Recognized amounts of identifiable assets acquired and liabilities assumed Inventory $ 459,123 Prepaid assets 1,743,555 Other current assets 2,525,886 Intangible assets - product marketing rights 22,700,000 Accrued liabilities (300,000 ) Accrued product program liabilities (6,683,932 ) Assumed fixed payment obligations $ (29,837,853 ) Total identifiable net assets (9,393,221 ) Goodwill $ 19,453,135 The fair values of intangible assets, including product technology rights were determined using variations of the income approach. Varying discount rates were also applied to the projected net cash flows. The Company believes the assumptions are representative of those a market participant would use in estimating fair value. The fair value of the net identifiable asset acquired was determined to be $22.7 ten Innovus Merger (Consumer Health Portfolio) On February 14, 2020, February 13, 2020 ( 380,000 $16.0 200,000 February 26, 2020 March 10, 2020. 100% On March 31, 2020, first 120,000 $2.0 $24 December 31, 2019. $0.3 three March 31, 2020. March 20, 2021, 103,000 one two $1.0 2020 $30.0 2020 $0.4 three March 31, 2021. $1.0 2020 not In addition, as part of the Innovus Merger, the Company assumed approximately $3.1 $0.8 $3.1 $2.2 180,000 February 14, 2020. $41,000 March 31, 2021 The following table summarized the fair value of assets acquired and liabilities assumed at the date of acquisition. These estimates are preliminary, pending final evaluation of certain assets and liabilities, and therefore, are subject to revisions that may As of February 14, 2020 Consideration Fair Value of Aytu Common Stock Total shares issued at close 3,810,393 Estimated fair value per share of Aytu common stock $ 0.756 Estimated fair value of equity consideration transferred $ 2,880,581 Fair value of Series H Convertible Preferred Stock Total shares issued 1,997,736 Estimated fair value per share of Aytu common stock $ 0.756 Estimated fair value of equity consideration transferred $ 1,510,288 Fair value of former Innovus warrants $ 15,315 Fair value of Contingent Value Rights 7,049,079 Forgiveness of Note Payable owed to the Company 1,350,000 Total consideration transferred $ 12,805,263 As of February 14, 2020 Total consideration transferred $ 12,805,263 Recognized amounts of identified assets acquired and liabilities assumed Cash and cash equivalents $ 390,916 Accounts receivable 278,826 Inventory 1,149,625 Prepaid expenses and other current assets 1,692,133 Other long-term assets 36,781 Right-to-use assets 328,410 Property, plant and equipment 190,393 Trademarks and patents 11,744,000 Accounts payable and accrued other expenses (7,202,309 ) Other current liabilities (629,601 ) Notes payable (3,056,361 ) Lease liability (754,822 ) Total identifiable net assets $ 4,167,991 Goodwill $ 8,637,272 The fair values of intangible assets, including product distribution rights were determined using variations of the income approach, specifically the relief-from-royalties method. It also includes customer lists using an income approach utilizing a discounted cash flow model. Varying discount rates were also applied to the projected net cash flows. The CVRs were valued using a Monte-Carlo model. The Company believes the assumptions are representative of those a market participant would use in estimating fair value (see Note 9 The fair value of the net identifiable assets acquired was determined to be $11.7 1.5 10 Neos Merger (ADHD Portfolio) On March 19, 2021, March 18, 2021 March 18, 2021. 5,472,000 100% $2.8 $0.1 The following table summarized the preliminary fair value of assets acquired and liabilities assumed at the date of acquisition. These estimates are preliminary, pending final evaluation of certain assets and liabilities, and therefore, are subject to revisions that may As of March 19, 2021 Considerations: Fair Value of Aytu Common Stock Total shares issued at close 5,471,804 Estimated fair value per share of Aytu common stock $ 9.73 Estimated fair value of equity consideration transferred $ 53,240,653 Cash 15,383,104 Estimated fair value of replacement equity awards 432,289 Total consideration transferred $ 69,056,046 As of March 19, 2021 Total consideration transferred $ 69,056,046 Recognized amounts of identified assets acquired and liabilities assumed Cash and cash equivalents $ 15,721,797 Accounts receivable 24,695,527 Inventory 10,984,055 Prepaid expenses and other current assets 2,929,457 Operating leases right-to-use assets 3,515,141 Property, plant and equipment 5,518,801 Intangible assets 56,530,000 Other long-term assets 148,931 Accounts payable and accrued expenses (56,718,159 ) Short-term line of credit (10,707,115 ) Long-term debt, including current portion (17,677,954 ) Operating lease liabilities (3,515,141 ) Other long-term liabilities (81,523 ) Total identifiable net assets $ 31,343,817 Goodwill $ 37,712,229 The fair values of intangible assets were determined using variations of the cost approach, excess earnings method and the relief-from-royalties method. The fair value of Neos trade name, in-process R&D and developed product technology, which is the proprietary technology for the development of Adzenys, Cotempla and generic Tussionex, were determined using the relief from royalty method. The fair value of developed technology right, which is a proprietary modified-release drug delivery technology, was determined using multi-period excess earnings method. The fair value of RxConnect, which is a developed technology for Neos-sponsored patient support program that offers affordable and predictable copays to all commercially insured patients, was determined using cost to recreate method. The finite-lived intangible assets are being amortized over a range of between 1 18 The fair value of the identifiable intangible assets acquired were as follows: As of March 19, 2021 Identified intangible assets acquired: Developed technology right $ 30,200,000 Developed products technology 22,700,000 In-process R&D 2,600,000 RxConnect 630,000 Trade name 400,000 Total intangible assets acquired $ 56,530,000 Unaudited Pro Forma Information The following supplemental unaudited proforma financial information presents the Company's results as if the following acquisitions had occurred on July 1, 2019: ● Acquisition of the Pediatric Portfolio, effective November 1, 2019; ● Merger with Innovus, effective February 14, 2020. ● Merger with Neos, effective March 19, 2021. The unaudited pro forma results have been prepared based on estimates and assumptions, which management believes are reasonable, however, the results are not July 1, 2019, Three Months Ended Nine Months Ended March 31, 2021 March 31, 2020 March 31, 2021 March 31, 2020 Actual Pro forma Actual Pro forma (Unaudited) (dd) (Unaudited) (aa) (bb) (Unaudited) (dd) (Unaudited) (cc) Total revenues, net $ 22,250,543 $ 24,824,477 $ 74,582,036 $ 83,141,373 Net (loss) $ (32,674,710 ) $ (13,800,554 ) $ (55,711,884 ) $ (31,686,745 ) Net (loss) per share (ee) $ (1.41 ) $ (3.91 ) $ (2.71 ) $ (14.01 ) (aa) For the three March 31, 2020, three March 31, 2020, three March 31, 2020. (bb) Due to the absence of discrete financial information for Innovus covering the period from January 1, 2020 February 13, 2020, not three nine March 31, 2020. (cc) Due to a lack of financial information covering the period from October 1, 2019 November 1, 2019, not nine March 31, 2020 not (dd) Neos contributed approximately $0.9 $3.9 March 20, 2021 March 31, 2021. (ee) Pro forma net loss per share calculations excluded the impact of the issuance of the (i) Series G Convertible Preferred Stock and the, (ii) Series H Convertible Preferred Stock under the assumption those shares would continue to remain non-participatory during the periods reported above.

Note 3 - Revenue Recognition

Note 3 - Revenue Recognition	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Contract Balances March 31, 2021, $42,000 no June 30, 2020. March 31, 2021 June 30, 2020, $0.2 $0.3 Revenues by Geographic location . Three Months Ended Nine Months Ended March 31, March 31, 2021 2020 2021 2020 U.S. $ 12,344,000 $ 7,273,000 $ 38,245,000 $ 11,582,000 International 1,138,000 883,000 3,905,000 1,189,000 Total net revenue $ 13,482,000 $ 8,156,000 $ 42,150,000 $ 12,771,000 Revenues by Product Portfolio. three nine March 31, 2021 March 31, 2020 Three Months Ended March 31, Nine Months Ended March 31, 2021 2020 2021 2020 Primary care and devices portfolio $ 1,209,000 $ 870,000 $ 8,339,000 $ 3,500,000 Pediatric portfolio 3,918,000 3,833,000 9,752,000 5,818,000 Consumer Health portfolio 8,355,000 3,453,000 24,059,000 3,453,000 Consolidated revenue $ 13,482,000 $ 8,156,000 $ 42,150,000 $ 12,771,000

Note 4 - Inventories

Note 4 - Inventories	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first first no first $7.0 $7.2 three nine March 31, 2021 19 no three nine March 31, 2020, Inventory balances consist of the following: As of As of March 31, June 30, 2021 2020 Raw materials $ 2,583,000 $ 397,000 Work in process 3,181,000 − Finished goods 10,812,000 9,603,000 Inventory $ 16,576,000 $ 10,000,000

Note 5 - Fixed Assets

Note 5 - Fixed Assets	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Fixed assets are recorded at cost and once placed in service, are depreciated on a straight-line basis over the estimated useful lives. Leasehold improvements are amortized over the shorter of the estimated economic life or related lease term. Fixed assets consist of the following: As of As of Estimated March 31, June 30, Useful Lives in years 2021 2020 Manufacturing equipment 2 7 $ 3,072,000 $ 112,000 Leasehold improvements 3 1,259,000 229,000 Office equipment, furniture and other 2 7 966,000 312,000 Lab equipment 3 7 646,000 90,000 Assets under construction 186,000 − Less accumulated depreciation and amortization (571,000 ) (484,000 ) Fixed assets, net $ 5,558,000 $ 259,000 During the nine March 31, 2021 $0.1 no three March 31, 2021. Depreciation and amortization expense totaled $68,000 $24,000 three March 31, 2021 2020 $119,000 $56,000 nine March 31, 2021 2020

Note 6 - Leases, Right-to-use A

Note 6 - Leases, Right-to-use Assets and Related Liabilities	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. The Company previously adopted the FASB issued ASU 2016 02, 842 July 1, 2019. 2016 02, July 1, 2019, 842, not Upon the closing of the Neos Merger on March 19, 2021, 805, $3.5 not 6.7% no twelve 5.9%. On August 28, 2020, September 30, 2020. April 30, 2023. two $44,306 $125,000 $20,881. $0.7 June 30, 2020 $343,000 nine March 31, 2021 On October 1, 2020, one six ninety not The components of lease expenses are as follows: Three Months Ended Nine Months Ended March 31, March 31, 2021 2020 2021 2020 Statement of Operations Classification Lease cost: Operating lease cost $ 69,000 $ 27,000 $ 128,000 $ 72,000 Operating expenses Short-term lease cost 7,000 − 7,000 − Operating expenses Finance lease cost: Amortization of leased assets 19,000 − 19,000 − Cost of sales Interest on lease liabilities 1,000 − 1,000 − Other (expense), net Total net lease cost $ 96,000 $ 27,000 $ 155,000 $ 72,000 Supplemental balance sheet information related to leases is as follows: March 31, 2021 June 30, 2020 Balance Sheet Classification Assets: Operating lease assets $ 3,782,000 $ 634,000 Operating lease right-of-use asset Finance lease assets 347,000 − Fixed assets, net Total leased assets $ 4,129,000 $ 634,000 Liabilities: Current: Operating leases $ 911,000 $ 300,000 Current portion of operating lease liabilities Finance leases 100,000 − Current portion of debt Long-term Operating leases 2,872,000 725,000 Long-term operating lease liabilities, net of current portion Finance leases 207,000 - Long-term debt, net of current portion Total lease liabilities $ 4,090,000 $ 1,025,000 Remaining lease term and discount rate used are as follows: March 31, 2021 June 30, 2020 Weighted-Average Remaining Lease Term (years) Operating lease assets 3.67 3.33 Finance lease assets 2.96 − Weighted-Average Discount Rate Operating lease assets 6.62 % 8.09 % Finance lease assets 6.40 % − Supplemental cash flow information related to lease is as follows: Nine Months Ended March 31, 2021 2020 Cash flow classification of lease payments: Operating cash flows from operating leases $ 128,000 $ 72,000 Operating cash flows from finance leases $ 1,000 $ - As of March 31, 2021 Operating Finance 2021 (remaining 3 months) $ 281,000 $ 29,000 2022 1,154,000 117,000 2023 1,182,000 105,000 2024 1,117,000 88,000 2025 557,000 − Total lease payments 4,291,000 339,000 Less: Imputed interest (508,000 ) (32,000 ) Lease liabilities $ 3,783,000 $ 307,000

Note 7 - Intangible Assets

Note 7 - Intangible Assets	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	7. The Company currently holds the following intangible asset portfolios as of March 31, 2021 July 1, 2020; ( November 1, 2019 February 14, 2020 March 19, 2021, ( NT0502 On March 31, 2021, July 29, 2019. $7.5 30 none $7.5 March 31, 2021, $4.3 no March 31, 2021. If acquired in an asset acquisition, the Company capitalized the acquisition cost of each licensed patent or tradename, which can include a combination of both upfront consideration, as well as the estimated future contingent consideration estimated at the acquisition date. If acquired in a business combination, the Company capitalizes the estimated fair value of the intangible asset or assets acquired, based primarily on a discounted cash flow model approach or relief-from-royalties model as further described in Note 2. The following table provides the summary of the Company's intangible assets as of March 31, 2021 June 30, 2020 March 31, 2021 Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Weighted-Average Remaining Life (in years) Licensed assets $ 23,649,000 $ (8,768,000 ) $ (4,286,000 ) $ 10,595,000 15.15 Acquired product technology right 45,400,000 (3,259,000 ) − 42,141,000 13.37 Acquired technology right 30,200,000 (57,000 ) − 30,143,000 16.97 Acquired product distribution rights 11,354,000 (1,697,000 ) − 9,657,000 7.03 Acquired in-process R&D 2,600,000 - − 2,600,000 Indefinite-lived Acquired commercial technology 630,000 (20,000 ) − 610,000 1.97 Acquired trade name 400,000 (6,000 ) − 394,000 0.97 Acquired customer lists 390,000 (293,000 ) − 97,000 0.37 Total $ 114,623,000 $ (14,100,000 ) $ (4,286,000 ) $ 96,237,000 13.56 June 30, 2020 Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Weighted-Average Remaining Life (in years) Licensed assets $ 23,649,000 $ (7,062,000 ) $ − $ 16,587,000 11.88 MiOXSYS Patent 380,000 (185,000 ) (195,000 ) − − Acquired product technology right 22,700,000 (1,513,000 ) − 21,187,000 9.34 Acquired product distribution rights 11,354,000 (565,000 ) − 10,789,000 7.78 Acquired customer lists 390,000 (98,000 ) − 292,000 1.12 Total $ 58,473,000 $ (9,423,000 ) $ (195,000 ) $ 48,855,000 9.11 The following table summarizes the estimated future amortization expense to be recognized over the next five Amortization 2021 (remaining 3 months) $ 2,234,500 2022 8,529,000 2023 7,981,000 2024 7,825,000 2025 7,591,000 Thereafter 59,476,500 Total future amortization expense $ 93,637,000 Certain of the Company's amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 20 $1.7 $1.4 three March 31, 2021 2020 $4.9 $2.9 nine March 31, 2021 2020

Note 8 - Accrued Liabilities

Note 8 - Accrued Liabilities	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	8. Accrued liabilities consist of the following: As of As of March 31, June 30, 2021 2020 Accrued settlement expense $ 150,000 $ 315,000 Accrued program liabilities 7,836,000 959,000 Accrued product-related fees 2,379,000 2,471,000 Accrued savings offers 19,218,000 − Accrued distributor fees 2,816,000 457,000 Credit card liabilities 657,000 510,000 Medicaid liabilities 1,948,000 1,842,000 Return reserve 5,592,000 1,329,000 Sales taxes payable 182,000 175,000 Other accrued liabilities* 2,404,000 588,000 Total accrued liabilities $ 43,182,000 $ 8,646,000 * Other accrued liabilities consist of franchise tax, accounting and legal fees, interest payable, merchant services charges, none five

Note 9 - Fair Value Considerati

Note 9 - Fair Value Considerations	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. The Company's asset and liability classified financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant derivative liability and contingent consideration. The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on Monte-Carlo models. The valuation policies are determined by management, and the Company's Board of Directors is informed of any policy change. Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three Level 1: Level 2: Level 3: no The Company's assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company's policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented. Recurring Fair Value Measurements The following table presents the Company's financial liabilities that were accounted for at fair value on a recurring basis as of March 31, 2021 June 30, 2020 Fair Value Measurements at March 31, 2021 Fair Value at March 31, 2021 Quoted Priced in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Recurring: Contingent consideration $ 14,904,000 $ – $ – $ 14,904,000 CVR liability 5,591,000 – – 5,591,000 Total $ 20,495,000 $ − $ − $ 20,495,000 Fair Value Measurements at June 30, 2020 Fair Value at June 30, 2020 Quoted Priced in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Recurring: Contingent consideration $ 13,588,000 $ – $ – $ 13,588,000 CVR liability 5,572,000 ) – – 5,572,000 ) Total $ 19,160,000 $ − $ − $ 19,160,000 Contingent Consideration. 3 not As of November 2, 2018, $8.8 March 31, 2021, $14.4 March 31, 2021 none no $3.0 November 2021, The contingent consideration related to the ZolpiMist royalty payments was valued at $2.6 June 11, 2018. March 31, 2021, $0.3 March 31, 2021 none no The Company recognized approximately $0.2 February 14, 2020 30% three nine March 31, 2021 2020 $15,000, $44,000, no March 31, 2021 Contingent value rights. $16.0 470,000 March 31, 2020, 120,000 first $2.0 $24.0 2019 March 20, 2021, 103,000 one two $1.0 2020 $30.0 2020 $1.0 2020 not three March 31, 2021 March 31, 2020 $0.1 $0.2 nine March 31, 2021 2020 $1.0 $0.2 not December 31, 2019. Summary of Level 3 The following table sets forth a summary of changes to those fair value measures using Level 3 nine March 31, 2021 CVR Liability Contingent Consideration Balance as of June 30, 2020 $ 5,572,000 $ 13,588,000 Included in earnings 1,019,000 1,999,000 Settlements (1,000,000 ) (683,000 ) Balance as of March 31, 2021 $ 5,591,000 $ 14,904,000 Significant Assumptions Contingent consideration. March 31, 2021 As of March 31, 2021 Contingent Consideration Credit risk assumption 20.80 % Sales volatility 45.00 % Credit spread 3.00 % Time steps per year 1 Number of iterations 500 Contingent value rights. March 31, 2021 As of March 31, 2021 Contingent Value Rights Credit risk assumption 9.6 % Time steps per year 30.00 Number of iterations 10,000

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and contingencies are described below and summarized by the following as of March 31, 2021 Total 2021 2022 2023 2024 2025 Thereafter Prescription database $ 1,145,000 $ 412,000 $ 733,000 $ − $ − $ − $ − Pediatric portfolio fixed payments and product minimums 15,000,000 825,000 3,300,000 3,300,000 3,300,000 3,300,000 975,000 Inventory purchase commitment 1,472,000 736,000 736,000 − − − − CVR liability 12,000,000 − 2,000,000 5,000,000 5,000,000 − − Product contingent liability 2,500,000 − − − − − 2,500,000 Product milestone payments 3,000,000 − 3,000,000 − − − − Total $ 35,117,000 $ 1,973,000 $ 9,769,000 $ 8,300,000 $ 8,300,000 $ 3,300,000 $ 3,475,000 Prescription Database In May 2016, $1.6 three January 2020, $0.6 Pediatric Portfolio Fixed Payments and Product Milestone The Company assumed two November 1, 2019 January 2021, $86,840, $15.0 January 2021. second $100,000 February 2026, $210,767 January 2020. On May 29, 2020, $15.0 In addition, the Company acquired a Supply and Distribution Agreement with Tris Pharma, Inc. ("TRIS"), (the “Karbinal Agreement”), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Karbinal Agreement was 20 23.5% third 23.5% 8.5%, 15% 2018 2019 The Karbinal Agreement make-whole payment is capped at $2.1 August 1 July 31, 70,000 2025. $30 70,000 2025. August $3.0 first $40.0 Inventory Purchase Commitment On May 1, 2020, 50 No. 207957 three 2022 $1.0 CVR Liability On February 14, 2020, February 13, 2020. first one On March 31, 2020, 120,000 $2.0 $24.0 December 31, 2019. $0.3 June 30, 2020 March 20, 2021, 103,000 one two $1.0 2020 $30.0 2020 $0.4 three March 31, 2021.The $1.0 2020 not Product Contingent Liability In February 2015, five $0.5 March 31, 2021, $0.2 Product Milestone Payments In connection with the Company's intangible assets, Aytu has certain milestone payments, totaling $3.0 not 9

Note 11 - Capital Structure

Note 11 - Capital Structure	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. The Company has 200 $0.0001 50 $0.0001 March 31, 2021 June 30, 2020 23,457,887 12,583,736 zero Included in the common stock outstanding are 274,635 In June 2020, 430,230 $6.8 $0.2 June 30, 2020. not three March 31, 2021, 352,912 $3.6 $1.6 nine March 31, 2021. June 2020 March 31, 2021, 783,142, $10.4 $1.8 The Company entered into three March 10, 2020, March 12, 2020 March 19, 2020 ( “March July 2020, $1.5 March 92,302 92,302 $15.99 March 2020 one $356,000 On December 10, 2020, $0.8 130,081 15 On December 10, 2020, 4,166,667 $0.0001 $6.00 30 625,000 4,791,667 $28.8 $2.6 $26.2 311,458 311,458 $7.50 125% five $1.3 On March 19, 2021, 5,447,000 24,804 2 On March 20, 2021, 103,000 one two $1.0 2020 $30.0 2020

Note 12 - Equity Incentive Plan

Note 12 - Equity Incentive Plan	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Aytu 2015 On June 1, 2015, 2015 2015 July 2017, 3.0 2015 2015 February 13, 2020, 5.0 2015 March 31, 2021 4,603,990 2015 Neos 2015 Pursuant to the Neos Merger, the Company assumed 69,721 35,728 April 19, 2021, 105,449 2015 2015 March 31, 2021, no 2015 Stock Options Employee Stock Options: The fair value of the options is calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The assumptions used to estimate the fair value of the options granted under the Neos 2015 As of March 31, 2021 Expected volatility 100.0 % Expected term (years) 4.00 Risk-free interest rate 0.73 % Dividend yield − Stock option activity is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life in Years Aggregate Intrinsic Value Outstanding June 30, 2020 76,614 $ 19.39 9.67 $ − Granted 69,721 − Forfeited/Cancelled (7,553 ) − Expired (2,528 ) − Outstanding at March 31, 2021 136,254 $ 13.14 6.12 $ − Exercisable at March 31, 2021 20,569 $ 87.86 8.56 $ − As of March 31, 2021 $0.5 3.3 Restricted Stock Restricted stock activity is as follows: Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life in Years Unvested at June 30, 2020 418,454 $ 14.69 6.4 Vested (143,977 ) Unvested at March 31, 2021 274,477 $ 16.27 6.2 Under the Aytu 2015 $4.0 March 31, 2021 6.2 158 2015 July 2026. $1.1 March 31, 2021 5.3 Restricted Stock Unit On March 31, 2021, 55,000 third April 1, 2022, 1/12 first third $7.60 Restricted stock unit activity is as follows: Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life in Years Unvested at June 30, 2020 Granted 90,728 $ 8.35 2.21 Vested (2,822 ) Forfeited (544 ) Unvested at March 31, 2021 87,362 $ 8.31 2.26 Under the Neos 2015 $0.6 March 31, 2021 2.2 Stock-based compensation expense related to the fair value of stock options and restricted stock was included in the statements of operations as set forth in the table below: Three Months Ended March 31, Nine Months Ended March 31, 2021 2020 2021 2020 Cost of sales $ 9,000 $ − $ 9,000 $ − Research and development 3,000 − 3,000 − Sales, general and administrative 1,514,000 264,000 2,473,000 591,000 Total stock-based compensation expense $ 1,526,000 $ 264,000 $ 2,485,000 $ 591,000 As of March 31, 2021, $0.1 The stock-based compensation expense included in the table above is attributable to stock options and restricted stock of $0.1 $1.3 three March 31, 2021 $0.3 $2.1 nine March 31, 2021. $7,000 $0.3 three March 31, 2020 $14,000 $0.6 nine March 31, 2020.

Note 13 - Warrants

Note 13 - Warrants	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Warrants or Rights Disclosure [Text Block]	13. In July 2020, 92,302 $15.99 March one $356,000 On December 15, 2020, 311,458 $7.50 December 15, 2020 $1.3 A summary of equity-based warrants is as follows: Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life in Years Outstanding June 30, 2020 2,288,528 $ 30.26 2.00 Warrants issued 403,760 Warrants expired (1,434,763 ) Outstanding March 31, 2021 1,257,525 $ 41.42 3.05

Note 14 - Net Loss Per Common S

Note 14 - Net Loss Per Common Share	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	14. Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. For each three 2020 2019, not The following table sets-forth securities that could be potentially dilutive, but as of March 31, 2021 2020 As of March 31, 2021 2020 Warrants to purchase common stock - liability classified 24,105 24,105 Warrant to purchase common stock - equity classified (Note 13) 1,257,525 3,098,604 Employee stock options (Note 12) 136,254 33,844 Employee unvested restricted stock (Note 12) 274,635 334,423 Employee unvested restricted stock units (Note 12) 87,362 − Convertible preferred stock (Note 11) − 980,584 Total 1,779,881 4,471,560

Note 15 - Debt

Note 15 - Debt	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	15. The Aytu BioPharma Note. February 27, 2020, $0.8 $0.6 eight November 1, 2020, $0.2 fourth 2020. three nine March 31, 2021 2020 $15,000 $70,000, December 10, 2020, 130,081 $0.8 March 31, 2021. $0.3 nine March 31, 2021. The Innovus Notes. January 9, 2020, $0.4 $0.5 twelve $45,000. March 31, 2021 The Neos Revolving Loans. October 2, 2019, $25.0 $2.5 may 85% one 4.50%. 0.50% May 11, 2022. In the event that, for any reason, all or any portion of the lender's commitment to make revolving loans is terminated prior to the scheduled maturity date, in addition to the payment of the principal amount and all unpaid accrued interest and other amounts due thereon, Neos is required to pay to the lender a prepayment fee equal to (i) 1.0% October 2, 2021, 0.5% October 2, 2021 May 11, 2022. may five The Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the Loan Agreement, including covenants and restrictions that, among other things, require Neos to satisfy certain capital expenditure and other financial covenants, and restrict Neos' ability to incur liens, incur additional indebtedness, engage in mergers and acquisitions or make asset sales without the prior written consent of the Lenders. A failure to comply with these covenants could permit the Lenders to declare Neos' obligations under the Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. Neos evaluated to determine if the embedded components in the agreement qualified as derivatives requiring separate recognition. In connection with the closing of the Neos Merger, Neos and Encina entered into a Consent, Waiver and First Amendment to the Loan Agreement, dated as of March 19, 2021 ( December 31, 2020 ( 3.1 Total interest expense was $28,000 March 20, 2021 March 31, 2021. March 31, 2021, $4.7 The Neos Senior Secured Credit Facility. May 11, 2016, $60.0 66 2/3% 33 1/3% March 19, 2021, $15.6 $0.6 April 11, 2021 May 11, 2022. June 2021, 12.95% not $5.0 Long-term debt consists of the following; March 31,2021 Senior secured credit facility, due on May 11, 2022 $ 15,625,000 Exit fee 1,000,000 Unamortized premium 724,000 Financing leases, maturing through May 2024 307,000 Total debt 17,656,000 Less: current portion (725,000 ) Long-term debt $ 16,931,000 In connection with the Neos Merger, Neos and Deerfield entered into a Consent, Waiver and Sixth Amendment to the Facility, dated as of March 19, 2021 ( May 11, 2016, $15.0 May 11, 2021 March 19, 2021, $15.0 March 19, 2021 May 11, 2021. Pursuant to the terms of the Facility, as amended, the $15.0 March 19, 2021, $16.6 805, $17.4 March 20, 2021. $0.8 March 31, 2021, $46,000 March 20, 2021 March 31, 2021. Future principal payments of long-term debt, including financing leases, are as follows: March 31,2021 2021 $ 650,000 2022 16,102,000 2023 96,000 2024 84,000 Future principal payments 16,932,000 Add unamortized premium 724,000 Less current portion (725,000 ) Long-term debt $ 16,931,000

Note 16 - Segment Reporting

Note 16 - Segment Reporting	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	16. The Company's chief operating decision maker (the “CODM”), who is the Company's Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance. The Company manages and aggregates its operational and financial information in accordance with two Select financial information for these segments is as follows: Three months Ended March 31, Nine Months Ended March 31, 2021 2020 2021 2020 Consolidated revenue: Aytu BioPharma $ 5,127,000 $ 4,703,000 $ 18,091,000 $ 9,318,000 Aytu Consumer Health 8,355,000 3,453,000 24,059,000 3,453,000 Consolidated revenue $ 13,482,000 $ 8,156,000 $ 42,150,000 $ 12,771,000 Consolidated net loss: Aytu BioPharma $ (23,570,000 ) $ (4,421,000 ) $ (34,788,000 ) $ (9,565,000 ) Aytu Consumer Health (1,890,000 ) (911,000 ) (4,503,000 ) (911,000 ) Consolidated net loss $ (25,460,000 ) $ (5,332,000 ) $ (39,291,000 ) $ (10,476,000 ) As of As of March 31, June 30, 2021 2020 Total assets: Aytu BioPharma $ 241,593,000 $ 126,267,000 Aytu Consumer Health 29,964,000 27,026,000 Total assets $ 271,557,000 $ 153,293,000

Note 17 - License Agreements

Note 17 - License Agreements	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Licensing Agreements [Text Block]	17. In October 2018, 101, NT0502. NT0502 $0.2 $0.2 first April 2020, first $0.3 may first Under the Teva Licensing Agreement, Neos granted Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under its ANDA beginning on July 1, 2026, Under the Actavis Licensing Agreement, Neos granted Actavis a non-exclusive license to certain patents owned by Neos by which Actavis has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, In July 2014, “2014 No. 204326 2014 $1.0 February 2016. In March 2017, “2017 No. 204325 2017 $1.0 October 2017. The royalties are recorded as cost of goods sold in the same period as the net sales upon which they are calculated. Additionally, each of the 2014 2017 not

Note 18 - Related Party Transac

Note 18 - Related Party Transactions	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	18. Tris Pharma, Inc. On November 2, 2018, November 1, 2019, 2 10 $0.9 $0 three March 31, 2021 2020 $22.8 $25.0 March 31, 2021 2020 October 2020, $1.6 March 19, 2021, no

Note 19 - Subsequent Events

Note 19 - Subsequent Events	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	19. On April 12, 2021, $1.5 $67.5 4 No. 333 239011 On May 17, 2021, not May 21, 2021

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation. 10 June 30, 2020 March 31, 2021 not March 31, 2021 three nine March 31, 2021 2020 On December 8, 2020, one 10
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent consideration, contingent value rights ("CVRs"), and fixed payment obligations at the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassification The Company historically presented accrued distributor fees as a reduction to accounts receivable. However, beginning this quarterly report and for the comparative periods presented, accrued distributors fees will be presented in accrued liabilities instead of accounts receivable. As of June 30, 2020, $457,000 no
New Accounting Pronouncements, Policy [Policy Text Block]	Adoption of New Accounting Pronouncements Fair Value Measurements ( ASU 2018 13 ). August 2018, 2018 13, 820 2018 13 820, December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 July 1, 2020, June 30, 2021. 2018 13 3 3 Recent Accounting Pronouncements Financial Instruments Credit Losses ( ASU 2016 13 ). June 2016, 2016 13, December 15, 2019. October 2019, December 15, 2022. June 30, 2024. December 15, 2018, not 2016 13 no This Quarterly Report on Form 10 not not

Note 2 - Acquisitions (Tables)

Note 2 - Acquisitions (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	As of November 1, 2019 Consideration Cash and cash equivalents $ 4,500,000 Fair value of Series G Convertible Preferred Stock Total shares issued 9,805,845 Estimated fair value per share of Aytu common stock $ 0.567 Estimated fair value of equity consideration transferred 5,559,914 Total consideration transferred $ 10,059,914 Recognized amounts of identifiable assets acquired and liabilities assumed Inventory $ 459,123 Prepaid assets 1,743,555 Other current assets 2,525,886 Intangible assets - product marketing rights 22,700,000 Accrued liabilities (300,000 ) Accrued product program liabilities (6,683,932 ) Assumed fixed payment obligations $ (29,837,853 ) Total identifiable net assets (9,393,221 ) Goodwill $ 19,453,135 As of February 14, 2020 Consideration Fair Value of Aytu Common Stock Total shares issued at close 3,810,393 Estimated fair value per share of Aytu common stock $ 0.756 Estimated fair value of equity consideration transferred $ 2,880,581 Fair value of Series H Convertible Preferred Stock Total shares issued 1,997,736 Estimated fair value per share of Aytu common stock $ 0.756 Estimated fair value of equity consideration transferred $ 1,510,288 Fair value of former Innovus warrants $ 15,315 Fair value of Contingent Value Rights 7,049,079 Forgiveness of Note Payable owed to the Company 1,350,000 Total consideration transferred $ 12,805,263 As of February 14, 2020 Total consideration transferred $ 12,805,263 Recognized amounts of identified assets acquired and liabilities assumed Cash and cash equivalents $ 390,916 Accounts receivable 278,826 Inventory 1,149,625 Prepaid expenses and other current assets 1,692,133 Other long-term assets 36,781 Right-to-use assets 328,410 Property, plant and equipment 190,393 Trademarks and patents 11,744,000 Accounts payable and accrued other expenses (7,202,309 ) Other current liabilities (629,601 ) Notes payable (3,056,361 ) Lease liability (754,822 ) Total identifiable net assets $ 4,167,991 Goodwill $ 8,637,272 As of March 19, 2021 Considerations: Fair Value of Aytu Common Stock Total shares issued at close 5,471,804 Estimated fair value per share of Aytu common stock $ 9.73 Estimated fair value of equity consideration transferred $ 53,240,653 Cash 15,383,104 Estimated fair value of replacement equity awards 432,289 Total consideration transferred $ 69,056,046 As of March 19, 2021 Total consideration transferred $ 69,056,046 Recognized amounts of identified assets acquired and liabilities assumed Cash and cash equivalents $ 15,721,797 Accounts receivable 24,695,527 Inventory 10,984,055 Prepaid expenses and other current assets 2,929,457 Operating leases right-to-use assets 3,515,141 Property, plant and equipment 5,518,801 Intangible assets 56,530,000 Other long-term assets 148,931 Accounts payable and accrued expenses (56,718,159 ) Short-term line of credit (10,707,115 ) Long-term debt, including current portion (17,677,954 ) Operating lease liabilities (3,515,141 ) Other long-term liabilities (81,523 ) Total identifiable net assets $ 31,343,817 Goodwill $ 37,712,229
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	As of March 19, 2021 Identified intangible assets acquired: Developed technology right $ 30,200,000 Developed products technology 22,700,000 In-process R&D 2,600,000 RxConnect 630,000 Trade name 400,000 Total intangible assets acquired $ 56,530,000
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Ended Nine Months Ended March 31, 2021 March 31, 2020 March 31, 2021 March 31, 2020 Actual Pro forma Actual Pro forma (Unaudited) (dd) (Unaudited) (aa) (bb) (Unaudited) (dd) (Unaudited) (cc) Total revenues, net $ 22,250,543 $ 24,824,477 $ 74,582,036 $ 83,141,373 Net (loss) $ (32,674,710 ) $ (13,800,554 ) $ (55,711,884 ) $ (31,686,745 ) Net (loss) per share (ee) $ (1.41 ) $ (3.91 ) $ (2.71 ) $ (14.01 )

Note 3 - Revenue Recognition (T

Note 3 - Revenue Recognition (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended Nine Months Ended March 31, March 31, 2021 2020 2021 2020 U.S. $ 12,344,000 $ 7,273,000 $ 38,245,000 $ 11,582,000 International 1,138,000 883,000 3,905,000 1,189,000 Total net revenue $ 13,482,000 $ 8,156,000 $ 42,150,000 $ 12,771,000
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, Nine Months Ended March 31, 2021 2020 2021 2020 Primary care and devices portfolio $ 1,209,000 $ 870,000 $ 8,339,000 $ 3,500,000 Pediatric portfolio 3,918,000 3,833,000 9,752,000 5,818,000 Consumer Health portfolio 8,355,000 3,453,000 24,059,000 3,453,000 Consolidated revenue $ 13,482,000 $ 8,156,000 $ 42,150,000 $ 12,771,000

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of As of March 31, June 30, 2021 2020 Raw materials $ 2,583,000 $ 397,000 Work in process 3,181,000 − Finished goods 10,812,000 9,603,000 Inventory $ 16,576,000 $ 10,000,000

Note 5 - Fixed Assets (Tables)

Note 5 - Fixed Assets (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of As of Estimated March 31, June 30, Useful Lives in years 2021 2020 Manufacturing equipment 2 7 $ 3,072,000 $ 112,000 Leasehold improvements 3 1,259,000 229,000 Office equipment, furniture and other 2 7 966,000 312,000 Lab equipment 3 7 646,000 90,000 Assets under construction 186,000 − Less accumulated depreciation and amortization (571,000 ) (484,000 ) Fixed assets, net $ 5,558,000 $ 259,000

Note 6 - Leases, Right-to-use_2

Note 6 - Leases, Right-to-use Assets and Related Liabilities (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended Nine Months Ended March 31, March 31, 2021 2020 2021 2020 Statement of Operations Classification Lease cost: Operating lease cost $ 69,000 $ 27,000 $ 128,000 $ 72,000 Operating expenses Short-term lease cost 7,000 − 7,000 − Operating expenses Finance lease cost: Amortization of leased assets 19,000 − 19,000 − Cost of sales Interest on lease liabilities 1,000 − 1,000 − Other (expense), net Total net lease cost $ 96,000 $ 27,000 $ 155,000 $ 72,000
Assets and Liabilities, Lessee [Table Text Block]	March 31, 2021 June 30, 2020 Balance Sheet Classification Assets: Operating lease assets $ 3,782,000 $ 634,000 Operating lease right-of-use asset Finance lease assets 347,000 − Fixed assets, net Total leased assets $ 4,129,000 $ 634,000 Liabilities: Current: Operating leases $ 911,000 $ 300,000 Current portion of operating lease liabilities Finance leases 100,000 − Current portion of debt Long-term Operating leases 2,872,000 725,000 Long-term operating lease liabilities, net of current portion Finance leases 207,000 - Long-term debt, net of current portion Total lease liabilities $ 4,090,000 $ 1,025,000
Lessee, Lease Information [Table Text Block]	March 31, 2021 June 30, 2020 Weighted-Average Remaining Lease Term (years) Operating lease assets 3.67 3.33 Finance lease assets 2.96 − Weighted-Average Discount Rate Operating lease assets 6.62 % 8.09 % Finance lease assets 6.40 % −
Lessee, Leases, Cash Flow Information [Table Text Block]	Nine Months Ended March 31, 2021 2020 Cash flow classification of lease payments: Operating cash flows from operating leases $ 128,000 $ 72,000 Operating cash flows from finance leases $ 1,000 $ -
Lessee, Lease Liability, Maturity [Table Text Block]	Operating Finance 2021 (remaining 3 months) $ 281,000 $ 29,000 2022 1,154,000 117,000 2023 1,182,000 105,000 2024 1,117,000 88,000 2025 557,000 − Total lease payments 4,291,000 339,000 Less: Imputed interest (508,000 ) (32,000 ) Lease liabilities $ 3,783,000 $ 307,000

Note 7 - Intangible Assets (Tab

Note 7 - Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	March 31, 2021 Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Weighted-Average Remaining Life (in years) Licensed assets $ 23,649,000 $ (8,768,000 ) $ (4,286,000 ) $ 10,595,000 15.15 Acquired product technology right 45,400,000 (3,259,000 ) − 42,141,000 13.37 Acquired technology right 30,200,000 (57,000 ) − 30,143,000 16.97 Acquired product distribution rights 11,354,000 (1,697,000 ) − 9,657,000 7.03 Acquired in-process R&D 2,600,000 - − 2,600,000 Indefinite-lived Acquired commercial technology 630,000 (20,000 ) − 610,000 1.97 Acquired trade name 400,000 (6,000 ) − 394,000 0.97 Acquired customer lists 390,000 (293,000 ) − 97,000 0.37 Total $ 114,623,000 $ (14,100,000 ) $ (4,286,000 ) $ 96,237,000 13.56 June 30, 2020 Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Weighted-Average Remaining Life (in years) Licensed assets $ 23,649,000 $ (7,062,000 ) $ − $ 16,587,000 11.88 MiOXSYS Patent 380,000 (185,000 ) (195,000 ) − − Acquired product technology right 22,700,000 (1,513,000 ) − 21,187,000 9.34 Acquired product distribution rights 11,354,000 (565,000 ) − 10,789,000 7.78 Acquired customer lists 390,000 (98,000 ) − 292,000 1.12 Total $ 58,473,000 $ (9,423,000 ) $ (195,000 ) $ 48,855,000 9.11
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization 2021 (remaining 3 months) $ 2,234,500 2022 8,529,000 2023 7,981,000 2024 7,825,000 2025 7,591,000 Thereafter 59,476,500 Total future amortization expense $ 93,637,000

Note 8 - Accrued Liabilities (T

Note 8 - Accrued Liabilities (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of As of March 31, June 30, 2021 2020 Accrued settlement expense $ 150,000 $ 315,000 Accrued program liabilities 7,836,000 959,000 Accrued product-related fees 2,379,000 2,471,000 Accrued savings offers 19,218,000 − Accrued distributor fees 2,816,000 457,000 Credit card liabilities 657,000 510,000 Medicaid liabilities 1,948,000 1,842,000 Return reserve 5,592,000 1,329,000 Sales taxes payable 182,000 175,000 Other accrued liabilities* 2,404,000 588,000 Total accrued liabilities $ 43,182,000 $ 8,646,000

Note 9 - Fair Value Considera_2

Note 9 - Fair Value Considerations (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at March 31, 2021 Fair Value at March 31, 2021 Quoted Priced in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Recurring: Contingent consideration $ 14,904,000 $ – $ – $ 14,904,000 CVR liability 5,591,000 – – 5,591,000 Total $ 20,495,000 $ − $ − $ 20,495,000 Fair Value Measurements at June 30, 2020 Fair Value at June 30, 2020 Quoted Priced in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Recurring: Contingent consideration $ 13,588,000 $ – $ – $ 13,588,000 CVR liability 5,572,000 ) – – 5,572,000 ) Total $ 19,160,000 $ − $ − $ 19,160,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	CVR Liability Contingent Consideration Balance as of June 30, 2020 $ 5,572,000 $ 13,588,000 Included in earnings 1,019,000 1,999,000 Settlements (1,000,000 ) (683,000 ) Balance as of March 31, 2021 $ 5,591,000 $ 14,904,000
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	As of March 31, 2021 Contingent Consideration Credit risk assumption 20.80 % Sales volatility 45.00 % Credit spread 3.00 % Time steps per year 1 Number of iterations 500 As of March 31, 2021 Contingent Value Rights Credit risk assumption 9.6 % Time steps per year 30.00 Number of iterations 10,000

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Contractual Obligation, Fiscal Year Maturity [Table Text Block]	Total 2021 2022 2023 2024 2025 Thereafter Prescription database $ 1,145,000 $ 412,000 $ 733,000 $ − $ − $ − $ − Pediatric portfolio fixed payments and product minimums 15,000,000 825,000 3,300,000 3,300,000 3,300,000 3,300,000 975,000 Inventory purchase commitment 1,472,000 736,000 736,000 − − − − CVR liability 12,000,000 − 2,000,000 5,000,000 5,000,000 − − Product contingent liability 2,500,000 − − − − − 2,500,000 Product milestone payments 3,000,000 − 3,000,000 − − − − Total $ 35,117,000 $ 1,973,000 $ 9,769,000 $ 8,300,000 $ 8,300,000 $ 3,300,000 $ 3,475,000

Note 12 - Equity Incentive Pl_2

Note 12 - Equity Incentive Plan (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	As of March 31, 2021 Expected volatility 100.0 % Expected term (years) 4.00 Risk-free interest rate 0.73 % Dividend yield −
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life in Years Aggregate Intrinsic Value Outstanding June 30, 2020 76,614 $ 19.39 9.67 $ − Granted 69,721 − Forfeited/Cancelled (7,553 ) − Expired (2,528 ) − Outstanding at March 31, 2021 136,254 $ 13.14 6.12 $ − Exercisable at March 31, 2021 20,569 $ 87.86 8.56 $ −
Nonvested Restricted Stock Shares Activity [Table Text Block]	Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life in Years Unvested at June 30, 2020 418,454 $ 14.69 6.4 Vested (143,977 ) Unvested at March 31, 2021 274,477 $ 16.27 6.2
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life in Years Unvested at June 30, 2020 Granted 90,728 $ 8.35 2.21 Vested (2,822 ) Forfeited (544 ) Unvested at March 31, 2021 87,362 $ 8.31 2.26
Share-based Payment Arrangement, Cost by Plan [Table Text Block]	Three Months Ended March 31, Nine Months Ended March 31, 2021 2020 2021 2020 Cost of sales $ 9,000 $ − $ 9,000 $ − Research and development 3,000 − 3,000 − Sales, general and administrative 1,514,000 264,000 2,473,000 591,000 Total stock-based compensation expense $ 1,526,000 $ 264,000 $ 2,485,000 $ 591,000

Note 13 - Warrants (Tables)

Note 13 - Warrants (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life in Years Outstanding June 30, 2020 2,288,528 $ 30.26 2.00 Warrants issued 403,760 Warrants expired (1,434,763 ) Outstanding March 31, 2021 1,257,525 $ 41.42 3.05

Note 14 - Net Loss Per Common_2

Note 14 - Net Loss Per Common Share (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of March 31, 2021 2020 Warrants to purchase common stock - liability classified 24,105 24,105 Warrant to purchase common stock - equity classified (Note 13) 1,257,525 3,098,604 Employee stock options (Note 12) 136,254 33,844 Employee unvested restricted stock (Note 12) 274,635 334,423 Employee unvested restricted stock units (Note 12) 87,362 − Convertible preferred stock (Note 11) − 980,584 Total 1,779,881 4,471,560

Note 15 - Debt (Tables)

Note 15 - Debt (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	March 31,2021 Senior secured credit facility, due on May 11, 2022 $ 15,625,000 Exit fee 1,000,000 Unamortized premium 724,000 Financing leases, maturing through May 2024 307,000 Total debt 17,656,000 Less: current portion (725,000 ) Long-term debt $ 16,931,000
Schedule of Maturities of Long-term Debt [Table Text Block]	March 31,2021 2021 $ 650,000 2022 16,102,000 2023 96,000 2024 84,000 Future principal payments 16,932,000 Add unamortized premium 724,000 Less current portion (725,000 ) Long-term debt $ 16,931,000

Note 16 - Segment Reporting (Ta

Note 16 - Segment Reporting (Tables)	9 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three months Ended March 31, Nine Months Ended March 31, 2021 2020 2021 2020 Consolidated revenue: Aytu BioPharma $ 5,127,000 $ 4,703,000 $ 18,091,000 $ 9,318,000 Aytu Consumer Health 8,355,000 3,453,000 24,059,000 3,453,000 Consolidated revenue $ 13,482,000 $ 8,156,000 $ 42,150,000 $ 12,771,000 Consolidated net loss: Aytu BioPharma $ (23,570,000 ) $ (4,421,000 ) $ (34,788,000 ) $ (9,565,000 ) Aytu Consumer Health (1,890,000 ) (911,000 ) (4,503,000 ) (911,000 ) Consolidated net loss $ (25,460,000 ) $ (5,332,000 ) $ (39,291,000 ) $ (10,476,000 ) As of As of March 31, June 30, 2021 2020 Total assets: Aytu BioPharma $ 241,593,000 $ 126,267,000 Aytu Consumer Health 29,964,000 27,026,000 Total assets $ 271,557,000 $ 153,293,000

Note 1 - Nature of Business, _2

Note 1 - Nature of Business, Financial Condition, Basis of Presentation (Details Textual)	Mar. 19, 2021USD ($)	Dec. 08, 2020	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2020USD ($)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance			$ 46,800,000		$ 46,800,000
Revenue from Contract with Customer, Including Assessed Tax			$ 13,482,282	$ 8,156,173	$ 42,149,561	$ 12,771,235
Increase (Decrease) in Revenues, Percentage			65.00%		230.00%
Net Cash Provided by (Used in) Operating Activities, Total			$ 19,700,000	$ 20,600,000	$ (19,677,832)	$ (20,609,198)
Assets, Current, Total			100,012,751		100,012,751		$ 75,422,565
Accounts Receivable, after Allowance for Credit Loss, Current, Total			28,228,434		28,228,434		5,632,717
Accrued Liabilities, Current, Total			43,181,920		43,181,920		8,645,984
Accrued Distributor Fees, Reclassified From Accounts Receivable To Accrued Liabilities [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total							(457,000)
Accrued Liabilities, Current, Total							$ 457,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		10
Neos Therapeutics, Inc. [Member]
Repayments of Long-term Debt, Total	$ 15,400,000
Payments for Merger Related Costs	$ 5,500,000
Acerus [Member]
Termination Agreement, Aggregate Amount			7,500,000		$ 7,500,000
Termination Agreement, Monthly Installment Payments			$ 250,000
Termination Agreement, Equal Monthly Installment Payment , Period (Month)			2 years 180 days

Note 2 - Acquisitions (Details

Note 2 - Acquisitions (Details Textual) - USD ($)		Mar. 31, 2021	Mar. 20, 2021	Mar. 19, 2021	Mar. 31, 2020	Mar. 20, 2020	Feb. 14, 2020	Feb. 13, 2020	Nov. 01, 2019	Jan. 31, 2021	Jun. 30, 2020	Jan. 31, 2020	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020
Business Combination, Acquisition Related Costs													$ 1,536,800		$ 311,083	$ 2,849,037	$ 1,533,723
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs													137,735	$ 101,537	4,523,884
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	[1]												22,250,543			74,582,036
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual	[1]												$ (32,674,710)			(55,711,884)
Innovus Pharmaceuticals [Member]
Business Combination, Contingent Value Rights, First Revenue Milestone			$ 30,000,000		$ 24,000,000										24,000,000		24,000,000
Innovus Pharmaceuticals [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)							380,000
Business Combination, Consideration Transferred, Contingent Value Rights							$ 16,000,000
Noncontrolling Interest, Ownership Percentage by Parent								100.00%
Neos Therapeutics, Inc. [Member]
Noncontrolling Interest, Ownership Percentage by Parent				100.00%
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs				$ 100,000
Series H Preferred Stock [Member] | Innovus Pharmaceuticals [Member]
Stock Issued During Period, Shares, Exercise of Warrants (in shares)							200,000
The Pediatric Portfolio [Member]
Payments to Acquire Businesses, Gross									$ 4,500,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)									9,805,845
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Minimum Annual Royalties									$ 2,100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total									$ 22,700,000
Finite-Lived Intangible Asset, Useful Life (Year)									10 years
The Pediatric Portfolio [Member] | Minimum [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Royalty Payments, Percentage of Revenues									12.00%
The Pediatric Portfolio [Member] | Maximum [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Royalty Payments, Percentage of Revenues									15.00%
The Pediatric Portfolio [Member] | Cerecor, Inc. [Member]
Business Combination, Consideration Transferred, Liabilities Incurred, Medicaid Rebates									$ 2,700,000
Business Combination, Consideration Transferred, Liabilities Incurred, Product Returns									800,000
Business Combination, Consideration Transferred, Liabilities Incurred									3,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Fixed and Variable Payments to Investor									25,600,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Fixed Monthly Payments to Investor									$ 100,000
Payments for Fixed Obligations to Investor										$ 15,000,000	$ 15,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Monthly Variable Payments to Investor, Percentage of Revenues									15.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Monthly Minimum Variable Payments to Investor									$ 100,000
Payments for Variable Monthly Obligation to Investor												$ 200,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Variable Payments to Investor									$ 9,500,000
The Pediatric Portfolio [Member] | Series G Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)									980,000
Innovus Pharmaceuticals [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)							3,810,393
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total							$ 11,744,000	$ 11,700,000
Business Combination, Consideration Transferred, Contingent Value Rights							7,049,079
Stock Issued During Period, Shares, Contingent Value Rights (in shares)			103,000		120,000	103,000							120,000
Stock Issued During Period, Value, Contingent Value Rights			$ 1,000,000		$ 2,000,000	$ 1							$ 1,000,000
Business Combination, Contingent Value Rights, First Revenue Milestone		$ 24,000,000	30,000,000		24,000,000	0.40							24,000,000		24,000,000	24,000,000	24,000,000
Gain (Loss) from Change in Fair Value of CVR			$ (100,000)		$ 300,000	$ 30							400,000		$ (200,000)	1,000,000	$ 200,000	$ 300,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt								3,100,000
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation							754,822	$ 800,000
Innovus Pharmaceuticals [Member] | Conversion of Notes Payable into Common Stock [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt		41,000											$ 41,000			$ 41,000
Debt Conversion, Original Debt, Amount							$ 2,200,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)							180,000
Innovus Pharmaceuticals [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)								1 year 182 days					1 year
Innovus Pharmaceuticals [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)								10 years					18 years
Innovus Pharmaceuticals [Member] | Series H Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)							1,997,736
Neos Therapeutics, Inc. [Member]
Payments to Acquire Businesses, Gross				$ 15,383,104
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)				5,471,804
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total				$ 56,530,000
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation				3,515,141
Business Combination, Acquisition Related Costs				$ 2,800,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual		900,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ (3,900,000)
[1]	Neos contributed approximately $0.9 million to net revenue and approximately $3.9 million to net loss for the period covering March 20, 2021 through March 31, 2021.

Note 2 - Acquisitions - Prelimi

Note 2 - Acquisitions - Preliminary Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Mar. 19, 2021	Feb. 14, 2020	Nov. 01, 2019	Mar. 31, 2021	Jun. 30, 2020	Feb. 13, 2020
Goodwill				$ 65,802,636	$ 28,090,407
Innovus Pharmaceuticals [Member]
Total shares issued (in shares)		3,810,393
Estimated fair value per share of Aytu common stock (in dollars per share)		$ 0.756
Estimated fair value of equity consideration transferred		$ 2,880,581
Total consideration transferred		12,805,263
Inventory		1,149,625
Prepaid assets		1,692,133
Intangible assets - product marketing rights		11,744,000				$ 11,700,000
Accrued liabilities		7,202,309
Total identifiable net assets		4,167,991
Goodwill		8,637,272
Fair value of former Innovus warrants		15,315
Fair value of Contingent Value Rights		7,049,079
Forgiveness of Note Payable owed to the Company		1,350,000
Total consideration transferred		12,805,263
Cash and cash equivalents		390,916
Accounts receivable		278,826
Other long-term assets		36,781
Right-to-use assets		328,410
Property, plant and equipment		190,393
Other current liabilities		629,601
Notes payable		3,056,361
Lease liability		$ 754,822				800,000
Total shares issued at close (in shares)		3,810,393
Inventory		$ 1,149,625
Operating leases right-to-use assets		328,410
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		11,744,000				11,700,000
Accounts payable and accrued expenses		(7,202,309)
Operating lease liabilities		$ (754,822)				$ (800,000)
Innovus Pharmaceuticals [Member] | Series H Preferred Stock [Member]
Total shares issued (in shares)		1,997,736
Estimated fair value per share of Aytu common stock (in dollars per share)		$ 0.756
Estimated fair value of equity consideration transferred		$ 1,510,288
Total shares issued at close (in shares)		1,997,736
Neos Therapeutics, Inc. [Member]
Cash and cash equivalents	$ 15,383,104
Total shares issued (in shares)	5,471,804
Estimated fair value per share of Aytu common stock (in dollars per share)	$ 9.73
Estimated fair value of equity consideration transferred	$ 53,240,653
Total consideration transferred	69,056,046
Inventory	10,984,055
Prepaid assets	2,929,457
Intangible assets - product marketing rights	56,530,000
Accrued liabilities	56,718,159
Total identifiable net assets	31,343,817
Goodwill	37,712,229
Total consideration transferred	69,056,046
Cash and cash equivalents	15,721,797
Accounts receivable	24,695,527
Other long-term assets	148,931
Right-to-use assets	3,515,141
Property, plant and equipment	5,518,801
Lease liability	$ 3,515,141
Total shares issued at close (in shares)	5,471,804
Estimated fair value of replacement equity awards	$ 432,289
Inventory	10,984,055
Operating leases right-to-use assets	3,515,141
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	56,530,000
Accounts payable and accrued expenses	(56,718,159)
Short-term line of credit	(10,707,115)
Long-term debt, including current portion	(17,677,954)
Operating lease liabilities	(3,515,141)
Other long-term liabilities	$ (81,523)
The Pediatric Portfolio [Member]
Cash and cash equivalents			$ 4,500,000
Total shares issued (in shares)			9,805,845
Estimated fair value per share of Aytu common stock (in dollars per share)			$ 0.567
Estimated fair value of equity consideration transferred			$ 5,559,914
Total consideration transferred			10,059,914
Inventory			459,123
Prepaid assets			1,743,555
Other current assets			2,525,886
Intangible assets - product marketing rights			22,700,000
Accrued liabilities			300,000
Accrued product program liabilities			6,683,932
Assumed fixed payment obligations			29,837,853
Total identifiable net assets			9,393,221
Goodwill			19,453,135
Total consideration transferred			$ 10,059,914
Total shares issued at close (in shares)			9,805,845
Inventory			$ 459,123
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total			22,700,000
Accounts payable and accrued expenses			$ (300,000)

Note 2 - Acquisitions - Identif

Note 2 - Acquisitions - Identifiable Intangible Assets Acqured (Details) - Neos Therapeutics, Inc. [Member]	Mar. 19, 2021USD ($)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 56,530,000
In Process Research and Development [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	2,600,000
Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	30,200,000
Developed Products Technology [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	22,700,000
RXConnect [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	630,000
Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 400,000

Note 2 - Acquisitions - Unaudit

Note 2 - Acquisitions - Unaudited Pro Forma Results (Details) - USD ($)		3 Months Ended				9 Months Ended
		Mar. 31, 2021		Mar. 31, 2020	[2],[3]	Mar. 31, 2021		Mar. 31, 2020	[4]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	[1]	$ 22,250,543				$ 74,582,036
Total revenues, net				$ 24,824,477				$ 83,141,373
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual	[1]	$ (32,674,710)				$ (55,711,884)
Net (loss)				$ (13,800,554)				$ (31,686,745)
Net (loss) per share (ee) (in dollars per share)	[5]	$ (1.41)	[1]	$ (3.91)		$ (2.71)	[1]	$ (14.01)
[1]	Neos contributed approximately $0.9 million to net revenue and approximately $3.9 million to net loss for the period covering March 20, 2021 through March 31, 2021.
[2]	Due to the absence of discrete financial information for Innovus covering the period from January 1, 2020 through February 13, 2020, the Company did not include the impact of that stub-period for the pro forma results for the three and nine months ended March 31, 2020.
[3]	For the three months ended March 31, 2020, the Pediatric Portfolio acquisition occurred prior to the three months ended March 31, 2020, and accordingly, the results of the Pediatric Portfolio are fully consolidated into the Company's results for the three months ended March 31, 2020.
[4]	Due to a lack of financial information covering the period from October 1, 2019 through November 1, 2019, the Company was not able to provide pro forma adjusted financial statements for the nine months ended March 31, 2020 without making estimated extrapolations that the Company did not believe would be material or useful to users of the above pro forma information.
[5]	Pro forma net loss per share calculations excluded the impact of the issuance of the (i) Series G Convertible Preferred Stock and the, (ii) Series H Convertible Preferred Stock under the assumption those shares would continue to remain non-participatory during the periods reported above.

Note 3 - Revenue Recognition (D

Note 3 - Revenue Recognition (Details Textual) - USD ($)	Mar. 31, 2021	Jun. 30, 2020
Other Current Assets [Member]
Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total	$ 42,000	$ 0
Accrued Liabilities Current [Member]
Contract with Customer, Liability, Current	$ 200,000	$ 300,000

Note 3 - Revenue Recognition -

Note 3 - Revenue Recognition - Revenues by Geographic Location (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Total net revenue	$ 13,482,282	$ 8,156,173	$ 42,149,561	$ 12,771,235
UNITED STATES
Total net revenue	12,344,000	7,273,000	38,245,000	11,582,000
Non-US [Member]
Total net revenue	$ 1,138,000	$ 883,000	$ 3,905,000	$ 1,189,000

Note 3 - Revenue Recognition _2

Note 3 - Revenue Recognition - Revenues by Product Portfolio (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Total net revenue	$ 13,482,282	$ 8,156,173	$ 42,149,561	$ 12,771,235
Primary Care and Devices [Member]
Total net revenue	1,209,000	870,000	8,339,000	3,500,000
Pediatric [Member]
Total net revenue	3,918,000	3,833,000	9,752,000	5,818,000
Consumer Health [Member]
Total net revenue	$ 8,355,000	$ 3,453,000	$ 24,059,000	$ 3,453,000

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Inventory Write-down	$ 7,000,000	$ 0	$ 7,227,230	$ 0

Note 4 - Inventories - Inventor

Note 4 - Inventories - Inventory Balances (Details) - USD ($)	Mar. 31, 2021	Jun. 30, 2020
Raw materials	$ 2,583,000	$ 397,000
Work in process	3,181,000
Finished goods	10,812,000	9,603,000
Inventory	$ 16,575,757	$ 9,999,441

Note 5 - Fixed Assets (Details

Note 5 - Fixed Assets (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Gain (Loss) on Disposition of Property Plant Equipment, Total	$ 0		$ (112,110)
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 68,000	$ 24,000	$ 119,000	$ 56,000

Note 5 - Fixed Assets - Fixed A

Note 5 - Fixed Assets - Fixed Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Jun. 30, 2020
Less accumulated depreciation and amortization	$ (571,000)	$ (484,000)
Fixed assets, net	5,557,727	258,516
Manufacturing Equipment [Member]
Fixed assets, gross	$ 3,072,000	112,000
Manufacturing Equipment [Member] | Minimum [Member]
Estimated useful life (Year)	2 years
Manufacturing Equipment [Member] | Maximum [Member]
Estimated useful life (Year)	7 years
Leasehold Improvements [Member]
Estimated useful life (Year)	3 years
Fixed assets, gross	$ 1,259,000	229,000
Office Equipment, Furniture and Other [Member]
Fixed assets, gross	$ 966,000	312,000
Office Equipment, Furniture and Other [Member] | Minimum [Member]
Estimated useful life (Year)	2 years
Office Equipment, Furniture and Other [Member] | Maximum [Member]
Estimated useful life (Year)	7 years
Lab Equipment [Member]
Fixed assets, gross	$ 646,000	90,000
Lab Equipment [Member] | Minimum [Member]
Estimated useful life (Year)	3 years
Lab Equipment [Member] | Maximum [Member]
Estimated useful life (Year)	7 years
Asset under Construction [Member]
Fixed assets, gross	$ 186,000

Note 6 - Leases, Right-to-use_3

Note 6 - Leases, Right-to-use Assets and Related Liabilities (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 19, 2021	Oct. 01, 2020	Aug. 28, 2020	Jun. 30, 2020
Operating Lease, Right-of-Use Asset	$ 3,781,737					$ 634,093
Operating Lease, Liability, Total	3,783,000
Gain (Loss) on Termination of Lease	343,185
Lease for Warehouse Space in Carlsbad, CA [Member]
Lessee, Operating Lease, Term of Contract (Year)				1 year
Innovus Pharmaceuticals [Member]
Lessee, Operating Lease, Termination Agreement, Two Months Rent					$ 44,306
Lessee, Operating Lease, Termination Agreement, Additional Fee					125,000
Security Deposit					$ 20,881
Operating Lease, Liability, Total						$ 700,000
Gain (Loss) on Termination of Lease	$ 343,000
Neos Therapeutics, Inc. [Member]
Operating Lease, Right-of-Use Asset			$ 3,500,000
Lessee, Operating Lease, Discount Rate			6.70%
Lessee, Finance Lease, Discount Rate			5.90%
Operating Lease, Liability, Total			$ 3,500,000

Note 6 - Leases, Right-to-use_4

Note 6 - Leases, Right-to-use Assets and Related Liabilities - Lease Expenses and Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Total net lease cost	$ 96,000	$ 27,000	$ 155,000	$ 72,000
Operating Expense [Member]
Operating lease cost	69,000	27,000	128,000	72,000
Short-term lease cost	7,000		7,000
Cost of Sales [Member]
Amortization of leased assets	19,000		19,000
Other Expense [Member]
Interest on lease liabilities	$ 1,000		$ 1,000

Note 6 - Leases, Right-to-use_5

Note 6 - Leases, Right-to-use Assets and Related Liabilities - Balance Sheet Information (Details) - USD ($)	Mar. 31, 2021	Jun. 30, 2020
Operating Lease, Right-of-Use Asset	$ 3,781,737	$ 634,093
Total leased assets	4,129,000	634,000
Operating leases liabilities	910,885	300,426
Operating leases, long-term	2,871,845	725,374
Total lease liabilities, long-term	4,090,000	1,025,000
Fixed Assets, Net [Member]
Finance lease assets	347,000
Current Portion of Debt [Member]
Finance leases liabilities	100,000
Long-term Debt, Net of Current Portion [Member]
Finance leases, long-term	$ 207,000

Note 6 - Leases, Right-to-use_6

Note 6 - Leases, Right-to-use Assets and Related Liabilities - Lease Information (Details)	Mar. 31, 2021	Jun. 30, 2020
Operating lease assets, weighted-average remaining lease term (years) (Year)	3 years 244 days	3 years 120 days
Finance lease assets, weighted-average remaining lease term (years) (Year)	2 years 350 days
Operating lease, weighted-average discount rate	6.62%	8.09%
Finance lease assets, weighted-average discount rate	6.40%

Note 6 - Leases, Right-to-use_7

Note 6 - Leases, Right-to-use Assets and Related Liabilities - Cash Flow Information (Details) - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating cash flows from operating leases	$ 128,000	$ 72,000
Operating cash flows from finance leases	$ 1,000

Note 6 - Leases, Right-to-use_8

Note 6 - Leases, Right-to-use Assets and Related Liabilities - Maturities of Lease Liabilities (Details)	Mar. 31, 2021USD ($)
2021 (remaining 3 months), operating	$ 281,000
2021 (remaining 3 months), finance	29,000
2022, operating	1,154,000
2022, finance	117,000
2023, operating	1,182,000
2023, finance	105,000
2024, operating	1,117,000
2024, finance	88,000
2025, operating	557,000
2025, finance
Total lease payments, operating	4,291,000
Total lease payments, finance	339,000
Less: Imputed interest, operating lease	(508,000)
Less: Imputed interest, finance	(32,000)
Lease liabilities, operating lease	3,783,000
Lease liabilities, finance	$ 307,000

Note 7 - Intangible Assets (Det

Note 7 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020
Impairment of Intangible Assets, Finite-lived	$ 4,286,000				$ 195,000
Finite-Lived Intangible Assets, Net, Ending Balance	93,637,000		$ 93,637,000
Amortization of Intangible Assets, Total	1,700,000	$ 1,400,000	$ 4,900,000	$ 2,900,000
Minimum [Member]
Finite-Lived Intangible Asset, Period before Next Renewal or Extension (Year)			1 year
Maximum [Member]
Finite-Lived Intangible Asset, Period before Next Renewal or Extension (Year)			20 years
Natesto [Member] | Licensed Asset [Member]
Impairment of Intangible Assets, Finite-lived	4,300,000
Finite-Lived Intangible Assets, Net, Ending Balance	0		$ 0
Neos Therapeutics, Inc. [Member]
Termination Agreement, Aggregate Amount	$ 7,500,000		$ 7,500,000
Termination Agreement, Equal Monthly Installment Payment , Period (Month)	2 years 180 days

Note 7 - Intangible Assets - Su

Note 7 - Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Jun. 30, 2020
Intangible assets, accumulated amortization	$ (14,100,000)	$ (9,423,000)
Intangible assets, impairment	(4,286,000)	$ (195,000)
Finite-Lived Intangible Assets, Net, Ending Balance	$ 93,637,000
Intangible assets, weighted-average remaining life (Year)	13 years 204 days	9 years 40 days
Intangible assets, gross carrying amount	$ 114,623,000	$ 58,473,000
Intangible assets, net carrying amount	96,236,796	48,854,561
In Process Research and Development [Member]
Indefinite-lived Intangible assets	2,600,000
Licensed Assets [Member]
Intangible assets, gross carrying amount	23,649,000	23,649,000
Intangible assets, accumulated amortization	(8,768,000)	(7,062,000)
Intangible assets, impairment	(4,286,000)
Finite-Lived Intangible Assets, Net, Ending Balance	$ 10,595,000	$ 16,587,000
Intangible assets, weighted-average remaining life (Year)	15 years 54 days	11 years 321 days
Technology-Based Intangible Assets [Member]
Intangible assets, gross carrying amount	$ 45,400,000	$ 22,700,000
Intangible assets, accumulated amortization	(3,259,000)	(1,513,000)
Intangible assets, impairment
Finite-Lived Intangible Assets, Net, Ending Balance	$ 42,141,000	$ 21,187,000
Intangible assets, weighted-average remaining life (Year)	13 years 135 days	9 years 124 days
MiOXSYS Patent [Member]
Intangible assets, gross carrying amount		$ 380,000
Intangible assets, accumulated amortization		(185,000)
Intangible assets, impairment		(195,000)
Finite-Lived Intangible Assets, Net, Ending Balance
Intangible assets, weighted-average remaining life (Year)
Developed Technology Rights [Member]
Intangible assets, gross carrying amount	$ 30,200,000
Intangible assets, accumulated amortization	(57,000)
Intangible assets, impairment
Finite-Lived Intangible Assets, Net, Ending Balance	$ 30,143,000
Intangible assets, weighted-average remaining life (Year)	16 years 354 days
Product Distribution Rights [Member]
Intangible assets, gross carrying amount	$ 11,354,000
Intangible assets, accumulated amortization	(1,697,000)
Intangible assets, impairment
Finite-Lived Intangible Assets, Net, Ending Balance	$ 9,657,000
Intangible assets, weighted-average remaining life (Year)	7 years 10 days
Distribution Rights [Member]
Intangible assets, gross carrying amount		$ 11,354,000
Intangible assets, accumulated amortization		(565,000)
Finite-Lived Intangible Assets, Net, Ending Balance		$ 10,789,000
Intangible assets, weighted-average remaining life (Year)		7 years 284 days
Customer Lists [Member]
Intangible assets, gross carrying amount	$ 390,000	$ 390,000
Intangible assets, accumulated amortization	(293,000)	(98,000)
Intangible assets, impairment
Finite-Lived Intangible Assets, Net, Ending Balance	$ 97,000	$ 292,000
Intangible assets, weighted-average remaining life (Year)	135 days	1 year 43 days
Commercial Technology [Member]
Intangible assets, gross carrying amount	$ 630,000
Intangible assets, accumulated amortization	(20,000)
Intangible assets, impairment
Finite-Lived Intangible Assets, Net, Ending Balance	$ 610,000
Intangible assets, weighted-average remaining life (Year)	1 year 354 days
Trade Names [Member]
Intangible assets, gross carrying amount	$ 400,000
Intangible assets, accumulated amortization	(6,000)
Intangible assets, impairment
Finite-Lived Intangible Assets, Net, Ending Balance	$ 394,000
Intangible assets, weighted-average remaining life (Year)	354 days

Note 7 - Intangible Assets - Am

Note 7 - Intangible Assets - Amortizable - Estimated Future Amortization Expense (Details)	Mar. 31, 2021USD ($)
2021 (remaining 3 months)	$ 2,234,500
2022	8,529,000
2023	7,981,000
2024	7,825,000
2025	7,591,000
Thereafter	59,476,500
Total future amortization expense	$ 93,637,000

Note 8 - Accrued Liabilities -

Note 8 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($)		Mar. 31, 2021	Jun. 30, 2020
Accrued settlement expense		$ 150,000	$ 315,000
Accrued program liabilities		7,836,000	959,000
Accrued product-related fees		2,379,000	2,471,000
Accrued savings offers		19,218,000
Accrued distributor fees		2,816,000	457,000
Credit card liabilities		657,000	510,000
Medicaid liabilities		1,948,000	1,842,000
Return reserve		5,592,000	1,329,000
Sales taxes payable		182,000	175,000
Other accrued liabilities*	[1]	2,404,000	588,000
Total accrued liabilities		$ 43,181,920	$ 8,645,984
[1]	Other accrued liabilities consist of franchise tax, accounting and legal fees, interest payable, merchant services charges, none of which individually represent greater than five percent of total current liabilities.

Note 9 - Fair Value Considera_3

Note 9 - Fair Value Considerations (Details Textual)	Mar. 20, 2021USD ($)shares	Mar. 31, 2020USD ($)shares	Mar. 20, 2020USD ($)shares	Nov. 30, 2021USD ($)	Mar. 31, 2021USD ($)shares	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Feb. 14, 2020USD ($)	Nov. 02, 2018USD ($)	Jun. 11, 2018USD ($)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability					$ (631,298)		$ 2,680,022
Tuzistra XR [Member]
Business Combination, Contingent Consideration, Liability, Total					14,400,000		14,400,000					$ 8,800,000
Tuzistra XR [Member] | Forecast [Member]
Payment for Contingent Consideration Liability, Operating Activities				$ 3,000,000
ZolpiMist [Member]
Business Combination, Contingent Consideration, Liability, Total										$ 300,000			$ 2,600,000
Innovus Pharmaceuticals [Member]
Business Combination, Contingent Consideration, Liability, Total											$ 200,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability					15,000	44,000
Business Combination, Contingent Value Rights, Maximum Range of Outcomes					$ 16,000,000		16,000,000
Business Combination, Maximum Shares to be Issued to Settle CVR (in shares) | shares					470,000
Stock Issued During Period, Shares, Contingent Value Rights (in shares) | shares	103,000	120,000	103,000		120,000
Stock Issued During Period, Value, Contingent Value Rights	$ 1,000,000	$ 2,000,000	$ 1		$ 1,000,000
Business Combination, Contingent Value Rights, First Revenue Milestone	30,000,000	24,000,000	0.40		24,000,000	24,000,000	24,000,000	24,000,000
Gain (Loss) from Change in Fair Value of CVR	$ (100,000)	$ 300,000	$ 30		$ 400,000	$ (200,000)	$ 1,000,000	$ 200,000	$ 300,000
Innovus Pharmaceuticals [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input											0.3

Note 9 - Fair Value Considera_4

Note 9 - Fair Value Considerations - Financial Liabilities Accounted for at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	Mar. 31, 2021	Jun. 30, 2020
Contingent consideration	$ 14,904,000	$ 13,588,000
CVR liability	5,591,000	5,572,000
Total	20,495,000	19,160,000
Fair Value, Inputs, Level 1 [Member]
Contingent consideration
CVR liability
Total
Fair Value, Inputs, Level 2 [Member]
Contingent consideration
CVR liability
Total
Fair Value, Inputs, Level 3 [Member]
Contingent consideration	14,904,000	13,588,000
CVR liability	5,591,000	5,572,000
Total	$ 20,495,000	$ 19,160,000

Note 9 - Fair Value Considera_5

Note 9 - Fair Value Considerations - Summary of Level 3 Input Changes (Details)	9 Months Ended
	Mar. 31, 2021USD ($)
CVR Liability [Member]
Balance	$ 5,572,000
Included in earnings	1,019,000
Settlements	(1,000,000)
Balance	5,591,000
Contingent Consideration [Member]
Balance	13,588,000
Included in earnings	1,999,000
Settlements	(683,000)
Balance	$ 14,904,000

Note 9 - Fair Value Considera_6

Note 9 - Fair Value Considerations - Significant Assumptions (Details)	Mar. 31, 2021
Credit Risk Assumption [Member]
Contingent consideration, measurement input	0.208
Contingent value rights, measurement input	0.096
Sales Volatility [Member]
Contingent consideration, measurement input	0.45
Time Steps Per Year [Member]
Contingent consideration, measurement input	1
Contingent value rights, measurement input	30
Credit Spread [Member]
Contingent consideration, measurement input	0.03
Number of Iterations [Member]
Contingent consideration, measurement input	500
Contingent value rights, measurement input	10,000

Note 10 - Commitments and Con_3

Note 10 - Commitments and Contingencies (Details Textual)	Mar. 20, 2021USD ($)shares	May 29, 2020USD ($)	Mar. 31, 2020USD ($)shares	Mar. 20, 2020USD ($)shares	Nov. 01, 2019USD ($)	Jan. 31, 2020USD ($)	May 31, 2016USD ($)	Mar. 31, 2021USD ($)shares	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jan. 31, 2021USD ($)	May 01, 2020USD ($)	Feb. 14, 2020USD ($)	Feb. 28, 2015USD ($)
Contractual Obligation, Total								$ 35,117,000		$ 35,117,000
Tris Pharma, Inc. [Member] | Karbinal Agreement [Member]
Supply and Distribution Commitment, Period (Year)					20 years
Supply and Distribution Commitment, Total Royalty, Percentage of Net Sales					23.50%
Supply and Distribution Commitment, Third Party, Royalty, Percentage of Net Sales					8.50%
Supply and Distribution Commitment, Royalty, Percentage of Net Sales													15.00%	15.00%
Supply and Distribution Agreement, Maximum Yearly Make-whole Payment					$ 2,100,000
Supply and Distribution Agreement, Minimum Sales Per Year					70,000
Supply and Distribution Agreement, Make-whole Payment Per Unit for Sales Under Minimum					$ 30
Supply and Distribution Agreement, Maximum Milestone Obligations					3,000,000
Supply and Distribution Agreement, First Milestone, Minimum Net Revenues					40,000,000
Innovus Pharmaceuticals [Member]
Stock Issued During Period, Shares, Contingent Value Rights (in shares) | shares	103,000		120,000	103,000				120,000
Stock Issued During Period, Value, Contingent Value Rights	$ 1,000,000		$ 2,000,000	$ 1				$ 1,000,000
Business Combination, Contingent Value Rights, First Revenue Milestone	30,000,000		24,000,000	0.40				24,000,000	$ 24,000,000	24,000,000	$ 24,000,000
Gain (Loss) from Change in Fair Value of CVR	$ (100,000)		$ 300,000	$ 30				400,000	$ (200,000)	1,000,000	$ 200,000	$ 300,000
Business Combination, Contingent Consideration, Liability, Total																	$ 200,000
Novalere [Member] | Innovus Pharmaceuticals [Member]
Business Acquisition, Contingent Consideration, Number of Payments																		5
Business Acquisition, Contingent Consideration, Payment Upon Each Sales Milestone																		$ 500,000
Business Combination, Contingent Consideration, Liability, Total								200,000		200,000
Prescription Database [Member]
Unrecorded Unconditional Purchase Obligation, Total							$ 1,600,000
Unrecorded Unconditional Purchase Obligation, Term (Year)							3 years
Contractual Obligation, Total								1,145,000		1,145,000
Prescription Database [Member] | The Pediatric Portfolio [Member]
Unrecorded Unconditional Purchase Obligation, Total						$ 600,000
First Pediatric Portfolio Fixed Obligation [Member]
Contractual Obligation, Monthly Payment															$ 86,840
Contractual Obligation, Balloon Payment															$ 15,000,000
Repayments of Fixed Obligation		$ 15,000,000
Second Pediatric Portfolio Fixed Obligation [Member]
Contractual Obligation, Monthly Payment					$ 100,000
Payments for Fixed Obligations to Investor						$ 210,767
Inventories [Member]
Contractual Obligation, Total								1,472,000		1,472,000
Inventories [Member] | Hikma Pharmaceuticals USA, Inc. [Member]
Unrecorded Unconditional Purchase Obligation, Total																$ 1,000,000
Product Milestone Payments [Member]
Contractual Obligation, Total								$ 3,000,000		$ 3,000,000

Note 10 - Commitments and Con_4

Note 10 - Commitments and Contingencies - Summary of Commitments and Contingencies (Details)	Mar. 31, 2021USD ($)
Total	$ 35,117,000
2021	1,973,000
2022	9,769,000
2023	8,300,000
2025	3,300,000
Thereafter	3,475,000
2021	1,973,000
Prescription Database [Member]
Total	1,145,000
2021	412,000
2022	733,000
2023
2024
2025
Thereafter
2021	412,000
Pediatric Portfolio Fixed Payments and Product Minimums [Member]
Total	15,000,000
2021	825,000
2022	3,300,000
2023	3,300,000
2024	3,300,000
2025	3,300,000
Thereafter	975,000
2021	825,000
Inventories [Member]
Total	1,472,000
2021	736,000
2022	736,000
2023
2024
2025
Thereafter
2021	736,000
CVR Liability [Member]
Total	12,000,000
2021
2022	2,000,000
2023	5,000,000
2024	5,000,000
2025
Thereafter
2021
Product Contingent Liability [Member]
Total	2,500,000
2021
2022
2023
2024
2025
Thereafter	2,500,000
2021
Product Milestone Payments [Member]
Total	3,000,000
2021
2022	3,000,000
2023
2025
Thereafter
2021

Note 11 - Capital Structure (De

Note 11 - Capital Structure (Details Textual) - USD ($)	Mar. 20, 2021	Mar. 19, 2021	Dec. 10, 2020	Mar. 31, 2020	Mar. 20, 2020	Jul. 31, 2020	Jun. 30, 2020	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021
Common Stock, Shares Authorized (in shares)							200,000,000	200,000,000	200,000,000		200,000,000		200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized (in shares)							50,000,000	50,000,000	50,000,000		50,000,000		50,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001		$ 0.0001
Common Stock, Shares, Outstanding, Ending Balance (in shares)							12,583,736	23,457,887			23,457,887		23,457,887
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							0	0	0		0		0
Stock Issued During Period, Value, New Issues									$ 28,317,444	$ 33,278,756
Payments of Stock Issuance Costs											$ 4,430,516	$ 5,280,426
Class of Warrant or Right, Issued During Period (in shares)											403,760
Neos Therapeutics, Inc. [Member]
Stock Issued During Period, Shares, Acquisitions (in shares)		5,447,000
Innovus Pharmaceuticals [Member]
Stock Issued During Period, Shares, Contingent Value Rights (in shares)	103,000			120,000	103,000			120,000
Stock Issued During Period, Value, Contingent Value Rights	$ 1,000,000			$ 2,000,000	$ 1			$ 1,000,000
Business Combination, Contingent Value Rights, First Revenue Milestone	$ 30,000,000			$ 24,000,000	$ 0.40			$ 24,000,000		$ 24,000,000	$ 24,000,000	$ 24,000,000	$ 24,000,000
Wainwright [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares)			4,791,667
Stock Issued During Period, Value, New Issues			$ 28,800,000
Payments of Stock Issuance Costs			$ 2,600,000
Underwriting Agreement, Commitment Offering, Shares (in shares)			4,166,667
Shares Issued, Price Per Share (in dollars per share)			$ 6
Underwriting Agreement, Overallotment Option, Shares (in shares)			625,000
Proceeds from Issuance of Common Stock			$ 26,200,000
Neos Directors and Officers [Member] | Neos Therapeutics, Inc. [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)		24,804
Conversion of Debt to Common Stock [Member]
Debt Conversion, Original Debt, Amount			$ 800,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)			130,081
Warrants Issued in Connection with March Offerings [Member]
Class of Warrant or Right, Issued During Period (in shares)						92,302
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						92,302
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)						$ 15.99
Warrants and Rights Outstanding, Term (Year)						1 year
Warrants and Rights Outstanding						$ 356,000
Warrants Issued in Connection With Wainwright Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)			311,458
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			311,458
Warrants and Rights Outstanding, Term (Year)			5 years
Warrants and Rights Outstanding			$ 1,300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 7.50
At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)							430,230	352,912					783,142
Stock Issued During Period, Value, New Issues							$ 6,800,000	$ 3,600,000					$ 10,400,000
Payments of Stock Issuance Costs							$ 200,000	$ 1,600,000					$ 1,800,000
The March Offerings [Member]
Payments of Stock Issuance Costs						$ 1,500,000
Restricted Stock [Member]
Common Stock, Shares, Outstanding, Ending Balance (in shares)								274,635			274,635		274,635

Note 12 - Equity Incentive Pl_3

Note 12 - Equity Incentive Plan (Details Textual) - USD ($)	Mar. 19, 2021	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Feb. 13, 2020	Jul. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		69,721	0
Share-based Payment Arrangement, Expense		$ 1,526,000		$ 264,000	$ 2,485,000	$ 591,000
Severance Agreements [Member] | Accrued Expense [Member]
Deferred Compensation Share-based Arrangements, Liability, Current		$ 100,000			$ 100,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		55,000			90,728
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 7.60			$ 8.35
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 500,000			$ 500,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		3 years 109 days
Share-based Payment Arrangement, Expense		$ 100,000		7,000	300,000	14,000
Restricted Stock [Member]
Share-based Payment Arrangement, Expense		$ 1,300,000		$ 300,000	$ 2,100,000	$ 600,000
The 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)							5,000,000	3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		4,603,990			4,603,990
The 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 73 days
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 600,000			$ 600,000
The 2015 Plan [Member] | Restricted Stock [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		6 years 73 days
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount		$ 4,000,000			4,000,000
Neos 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	105,449
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	69,721
Neos 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in shares)	35,728
Non-plan [Member] | Restricted Stock [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		5 years 109 days
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount		$ 1,100,000			$ 1,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)		158			158

Note 12 - Equity Incentive Pl_4

Note 12 - Equity Incentive Plan - Stock Option (Details) - Share-based Payment Arrangement, Option [Member]	3 Months Ended
	Mar. 31, 2021
Expected volatility	100.00%
Expected term (years) (Year)	4 years
Risk-free interest rate	0.73%
Dividend yield

Note 12 - Equity Incentive Pl_5

Note 12 - Equity Incentive Plan - Stock Option Activity (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020
Outstanding, number of options (in shares)	76,614
Outstanding, weighted average exercise price (in dollars per share)	$ 19.39
Outstanding, weighted average remaining contractual life (Year)	6 years 43 days		9 years 244 days
Granted, number of options (in shares)	69,721	0
Granted, weighted average exercise price (in dollars per share)
Forfeited/Cancelled, number of options (in shares)	(7,553)
Forfeited/Cancelled, weighted average exercise price (in dollars per share)
Expired, number of options (in shares)	(2,528)
Expired, weighted average exercise price (in dollars per share)
Outstanding, number of options (in shares)	136,254	76,614
Outstanding, weighted average exercise price (in dollars per share)	$ 13.14	$ 19.39
Outstanding, aggregate intrinsic value
Exercisable at March 31, 2021 (in shares)	20,569
Exercisable at March 31, 2021 (in dollars per share)	$ 87.86
Exercisable at March 31, 2021 (Year)	8 years 204 days
Exercisable at March 31, 2021

Note 12 - Equity Incentive Pl_6

Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details) - Restricted Stock [Member] - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2021	Jun. 30, 2020
Unvested at June 30, 2020 (in shares)	418,454
Unvested at June 30, 2020 (in dollars per share)	$ 14.69
Unvested at June 30, 2020 (Year)	6 years 73 days	6 years 146 days
Vested, number of shares (in shares)	(143,977)
Unvested at March 31, 2021 (in shares)	274,477	418,454
Unvested at March 31, 2021 (in dollars per share)	$ 16.27	$ 14.69

Note 12 - Equity Incentive Pl_7

Note 12 - Equity Incentive Plan - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2021	Jun. 30, 2020
Granted number of shares (in shares)	55,000	90,728
Granted, weighted average grant date fair value (in dollars per share)	$ 7.60	$ 8.35
Granted (Year)			2 years 76 days
Vested, number of shares (in shares)		(2,822)
Forfeited number of shares (in shares)		(544)
Unvested at March 31, 2021 (in shares)	87,362	87,362
Unvested, weighted average grant date fair value (in dollars per share)	$ 8.31	$ 8.31
Unvested at June 30, 2020 (Year)		2 years 94 days

Note 12 - Equity Incentive Pl_8

Note 12 - Equity Incentive Plan - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Total stock-based compensation expense	$ 1,526,000	$ 264,000	$ 2,485,000	$ 591,000
Cost of Sales [Member]
Total stock-based compensation expense	9,000		9,000
Research and Development Expense [Member]
Total stock-based compensation expense	3,000		3,000
Selling, General and Administrative Expenses [Member]
Total stock-based compensation expense	$ 1,514,000	$ 264,000	$ 2,473,000	$ 591,000

Note 13 - Warrants (Details Tex

Note 13 - Warrants (Details Textual) - USD ($)	Dec. 15, 2020	Jul. 31, 2020	Mar. 31, 2021
Class of Warrant or Right, Issued During Period (in shares)			403,760
Warrants Issued in Connection with March Offerings [Member]
Class of Warrant or Right, Issued During Period (in shares)		92,302
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)		$ 15.99
Warrants and Rights Outstanding, Term (Year)		1 year
Warrants and Rights Outstanding		$ 356,000
December 15, 2020 Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)	311,458
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)	$ 7.50
Warrants and Rights Outstanding	$ 1,300,000

Note 13 - Warrants - Summary of

Note 13 - Warrants - Summary of Equity-based Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2021	Jun. 30, 2020
Outstanding, number of warrants (in shares)	2,288,528
Outstanding, weighted average remaining contractual life (Year)	3 years 18 days	2 years
Warrants issued, number of warrants (in shares)	403,760
Warrants expired, number of warrants (in shares)	(1,434,763)
Outstanding, number of warrants (in shares)	1,257,525	2,288,528
Weighted Average [Member]
Outstanding, weighted average exercise price (in dollars per share)	$ 30.26
Outstanding, weighted average exercise price (in dollars per share)	$ 41.42	$ 30.26

Note 14 - Net Loss Per Common_3

Note 14 - Net Loss Per Common Share - Antidilutive Securities Excluded from Calculation of Diluted Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive securities (in shares)	1,779,881	4,471,560
Liability Warrants [Member]
Antidilutive securities (in shares)	24,105	24,105
Equity-based Warrants [Member]
Antidilutive securities (in shares)	1,257,525	3,098,604
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	136,254	33,844
Restricted Stock [Member]
Antidilutive securities (in shares)	274,635	334,423
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	87,362
Convertible Preferred Stock [Member]
Antidilutive securities (in shares)		980,584

Note 15 - Debt (Details Textual

Note 15 - Debt (Details Textual) - USD ($)	Mar. 31, 2021	Mar. 19, 2021	Dec. 10, 2020	Nov. 01, 2020	Jan. 09, 2020	Oct. 02, 2019	Feb. 27, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 20, 2021	May 11, 2016
Gain (Loss) on Exchange of Debt										$ (257,559)
Repayments of Debt										318,181
Neos Therapeutics, Inc. [Member]
Debt Instrument, Unamortized Premium, Total	$ 724,000							724,000		724,000
Neos Therapeutics, Inc. [Member] | Loan Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity						$ 25,000,000
Line of Credit Facility, Maximum Borrowing Capacity, Portion Available for Short-term Swingline Loans						$ 2,500,000
Percentage of Eligible Accounts Receivable Against which Short-term Swingline Loans May Be Made						85.00%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage						0.50%
Debt Instrument, Prepayment Option, Period of Notice Required (Day)						5 days
Interest Expense, Debt, Total	28,000
Long-term Line of Credit, Total	$ 4,700,000							$ 4,700,000		$ 4,700,000
Neos Therapeutics, Inc. [Member] | Loan Agreement [Member] | Event Occurs On or Before October 2, 2021 [Member]
Line of Credit Facility, Prepayment Fee Percentage						1.00%
Neos Therapeutics, Inc. [Member] | Loan Agreement [Member] | Event Occurs After October 2, 2021 but Before May 11, 2022 [Member]
Line of Credit Facility, Prepayment Fee Percentage						0.50%
Neos Therapeutics, Inc. [Member] | Loan Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate						4.50%
Neos Therapeutics, Inc. [Member] | Senior Secured Credit Facility, Due on May 11, 2022 [Member]
Debt Instrument, Face Amount													$ 60,000,000
Long-term Debt, Total		$ 15,600,000
Long-term Debt, Current Maturities, Total		600,000
Debt Instrument, Interest Rate, Stated Percentage	12.95%							12.95%		12.95%
Debt Instrument, Covenant, Cash and Certain Cash Equivalents, Minimum	$ 5,000,000							$ 5,000,000		$ 5,000,000
Repayments of Debt		15,000,000
Long-term Debt, Gross	15,625,000	$ 16,600,000						$ 15,625,000		15,625,000
Long-term Debt, Fair Value												$ 17,400,000
Debt Instrument, Unamortized Premium, Total												$ 800,000
Interest Expense, Debt, Excluding Amortization	$ 46,000
Conversion of Debt to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)			130,081
Debt Conversion, Original Debt, Amount			$ 800,000
Gain (Loss) on Exchange of Debt			$ (300,000)
Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount							$ 800,000
Proceeds from Notes Payable, Total							$ 600,000
Debt Instrument, Term (Month)				240 days
Debt Instrument, Unamortized Discount (Premium), Net, Total				$ 200,000
Amortization of Debt Discount (Premium)										$ 15,000	$ 70,000
Notes Payable, Other Payables [Member] | Innovus Pharmaceuticals [Member]
Debt Instrument, Face Amount					$ 500,000
Proceeds from Notes Payable, Total					$ 400,000
Debt Instrument, Term (Month)					1 year
Debt Instrument, Periodic Payment, Total					$ 45,000

Note 15 - Debt - Long-term Debt

Note 15 - Debt - Long-term Debt (Details) - USD ($)	Mar. 31, 2021	Mar. 20, 2021	Mar. 19, 2021
Financing leases, maturing through May 2024	$ 307,000
Neos Therapeutics, Inc. [Member]
Exit fee	1,000,000
Unamortized premium	724,000
Financing leases, maturing through May 2024	307,000
Total debt	17,656,000
Less: current portion	(725,000)
Long-term debt	16,931,000
Senior Secured Credit Facility, Due on May 11, 2022 [Member] | Neos Therapeutics, Inc. [Member]
Senior secured credit facility, due on May 11, 2022	$ 15,625,000		$ 16,600,000
Unamortized premium		$ 800,000

Note 15 - Debt - Long-term De_2

Note 15 - Debt - Long-term Debt Maturities (Details) - Neos Therapeutics, Inc. [Member]	Mar. 31, 2021USD ($)
2021, long-term debt and financing leases	$ 650,000
2022, long-term debt and financing leases	16,102,000
2023, long-term debt and financing leases	96,000
2024, long-term debt and financing leases	84,000
Future principal payments	16,932,000
Unamortized premium	724,000
Less: current portion	(725,000)
Long-term debt	$ 16,931,000

Note 16 - Segment Reporting (De

Note 16 - Segment Reporting (Details Textual)	6 Months Ended
	Dec. 31, 2020
Number of Reportable Segments	2

Note 16 - Segment Reporting - S

Note 16 - Segment Reporting - Select Financial Information for Segments (Details) - USD ($)	3 Months Ended						9 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020
Revenue	$ 13,482,000			$ 8,156,000			$ 42,150,000	$ 12,771,000
Net loss	(25,459,791)	$ (9,525,294)	$ (4,305,931)	(5,332,305)	$ (214,247)	$ (4,929,030)	(39,291,016)	(10,475,582)
Total assets	271,556,601						271,556,601		$ 153,293,123
Total assets	271,556,601						271,556,601		153,293,123
Aytu Bioscience [Member]
Revenue	5,127,000			4,703,000			18,091,000	9,318,000
Net loss	(23,570,000)			(4,421,000)			(34,788,000)	(9,565,000)
Total assets	241,593,000						241,593,000		126,267,000
Total assets	241,593,000						241,593,000		126,267,000
Aytu Consumer Health [Member]
Revenue	8,355,000			3,453,000			24,059,000	3,453,000
Net loss	(1,890,000)			$ (911,000)			(4,503,000)	$ (911,000)
Total assets	29,964,000						29,964,000		27,026,000
Total assets	$ 29,964,000						$ 29,964,000		$ 27,026,000

Note 17 - License Agreements (D

Note 17 - License Agreements (Details Textual) - USD ($) $ in Millions	1 Months Ended			12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017	Feb. 29, 2016	Dec. 31, 2020
License Agreement 2014 [Member] | Maximum [Member] | Neos Therapeutics, Inc. [Member]
Lump Sum, Non-refundable License Fee			$ 1
License Agreement 2017 [Member] | Maximum [Member] | Neos Therapeutics, Inc. [Member]
Lump Sum, Non-refundable License Fee		$ 1
NeuRx License, Royalty Bearing License Agreement [Member]
Payments for License Agreement	$ 0.2			$ 0.2
Payments for Contingent Consideration on License Agreement				$ 0.3

Note 18 - Related Party Trans_2

Note 18 - Related Party Transactions (Details Textual) - Tris Pharma, Inc. [Member] - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Oct. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Tris License Agreement [Member]
Related Party Transaction, Amounts of Transaction		$ 900	$ 0
Due to Related Parties, Total		$ 22,800	$ 25,000
Karbinal Fixed Payment Obligation [Member]
Related Party Transaction, Amounts of Transaction	$ 1,600

Note 19 - Subsequent Events (De

Note 19 - Subsequent Events (Details Textual) - Purchase of Certain Rights and Other Assets from Sellers [Member] - Subsequent Event [Member] $ in Millions	Apr. 12, 2021USD ($)
Payments to Acquire Productive Assets, Total	$ 1.5
Asset Purchase, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 67.5